<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006872" GROUP_ID="RENAL" ID="470606120401522845" MERGED_FROM="" MODIFIED="2010-03-25 01:13:37 +0100" MODIFIED_BY="Narelle Willis" REVIEW_NO="079" REVMAN_SUB_VERSION="5.0.23" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2010-03-25 01:13:37 +0100" MODIFIED_BY="Narelle Willis">
<TITLE>Prostaglandin E1 for preventing the progression of diabetic kidney disease</TITLE>
<CONTACT MODIFIED="2010-03-25 01:13:37 +0100" MODIFIED_BY="Narelle Willis"><PERSON ID="2CDB267882E26AA201BA4B5422E36CF1" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Jue Lin</FIRST_NAME><LAST_NAME>Deng</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>juelind2005@yahoo.com.cn</EMAIL_1><ADDRESS><DEPARTMENT>Department of Geriatrics</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>37 Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 028 85482676</PHONE_1><FAX_1>+86 028 81378788</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-03-25 01:13:37 +0100" MODIFIED_BY="Narelle Willis"><PERSON ID="2CE01F0482E26AA201BA4B54D6E57099" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Han</FIRST_NAME><LAST_NAME>Wang</LAST_NAME><POSITION>Attending doctor</POSITION><EMAIL_1>wh7967@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Geriatrics</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>37 Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 138 8070 5460</PHONE_1></ADDRESS></PERSON><PERSON ID="2CDB267882E26AA201BA4B5422E36CF1" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Jue Lin</FIRST_NAME><LAST_NAME>Deng</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>juelind2005@yahoo.com.cn</EMAIL_1><ADDRESS><DEPARTMENT>Department of Geriatrics</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>37 Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 028 85482676</PHONE_1><FAX_1>+86 028 81378788</FAX_1></ADDRESS></PERSON><PERSON ID="9B8AADCB82E26AA2014A5594ACA79479" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jirong</FIRST_NAME><LAST_NAME>Yue</LAST_NAME><SUFFIX>MSc</SUFFIX><POSITION>Lecturer</POSITION><EMAIL_1>Yuejirong11@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Geriatrics</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37 Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 85422326</PHONE_1></ADDRESS></PERSON><PERSON ID="19636" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jun</FIRST_NAME><LAST_NAME>Li</LAST_NAME><POSITION>Attending Physician</POSITION><EMAIL_1>jundream2003@yahoo.com.cn</EMAIL_1><ADDRESS><DEPARTMENT>Department of Geriatrics</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 028 85421791</PHONE_1></ADDRESS></PERSON><PERSON ID="2CE64F1782E26AA201BA4B542C09E2C0" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Yan Bin</FIRST_NAME><LAST_NAME>Hou</LAST_NAME><EMAIL_1>305948842@163.com</EMAIL_1><MOBILE_PHONE>+86 13408414448</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Geriatrics</DEPARTMENT><ORGANISATION>Kangning Hospital</ORGANISATION><CITY>Ningbo</CITY><REGION>Zhejiang</REGION><COUNTRY CODE="CN">China</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-03-25 11:06:19 +1100" MODIFIED_BY="Narelle S Willis">
<UP_TO_DATE>
<DATE DAY="12" MONTH="2" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="2" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="8" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2008-12-23 10:26:31 +1100" MODIFIED_BY="Narelle S Willis"/>
<HISTORY MODIFIED="2008-12-23 10:26:31 +1100" MODIFIED_BY="Narelle S Willis">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-12-23 10:26:31 +1100" MODIFIED_BY="Narelle S Willis">
<DATE DAY="13" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-02-09 16:20:52 +1100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2009-05-18 15:11:38 +1000" MODIFIED_BY="Narelle S Willis">
<SOURCE>
<NAME>Department of Geriatrics, West China Hospital, Sichuan University</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2009-05-18 15:11:38 +1000" MODIFIED_BY="Narelle S Willis">
<NAME>Chinese Cochrane Centre, Chinese Centre of Evidence-Based Medicine, West China Hospital of Sichuan University</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-03-25 11:06:50 +1100" MODIFIED_BY="Narelle S Willis">
<SUMMARY MODIFIED="2010-03-25 11:05:09 +1100" MODIFIED_BY="Narelle S Willis">
<TITLE MODIFIED="2010-03-16 22:37:07 +1100" MODIFIED_BY="[Empty name]">Prostaglandin E1 for preventing the progression of diabetic kidney disease</TITLE>
<SUMMARY_BODY MODIFIED="2010-03-25 11:05:09 +1100" MODIFIED_BY="Narelle S Willis">
<P>Continuous albuminuria (protein in the urine) is the major characteristic of diabetic kidney disease (DKD), which is regarded primary cause of death and poor health in patients with diabetes mellitus, leading to end-stage-kidney disease. While blood pressure medication (such as angiotensin-converting enzyme inhibitors (ACEi), calcium channel blockers and angiotensin-receptor blockers (ARB)) has been used/recommended for reducing albuminuria and preventing the progression of DKD, the incidence of DKD is still increasing among developed and developing countries. Prostaglandin E1 (PGE1) is a vasodilator agent which is thought to contribute to releasing intraglomerular pressure, increasing kidney blood circulation and reducing albuminuria. This review identified six studies (271 participants) comparing PGE1 with or without ACEi/ARB versus ACEi/ARB, no treatment or Xueshuantong (a Chinese medicinal herb). The results suggest that PGE1 may have a positive effect on DKD by reducing urinary albumin excretion rate (UAER), microalbuminuria and proteinuria. No serious adverse events or allergic responses were reported. All studies were methodologically poor and there is no strong evidence for recommending PGE1 for preventing the progression of DKD as a routine therapeutic measure. More high-quality research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-03-25 11:03:40 +1100" MODIFIED_BY="Narelle S Willis">
<ABS_BACKGROUND MODIFIED="2010-03-16 22:35:18 +1100" MODIFIED_BY="[Empty name]">
<P>Diabetic kidney disease (DKD) is one of the major chronic microvascular complications in diabetes mellitus, and may progress to end-stage kidney disease (ESKD). There are no definitely effective approaches for preventing, delaying or treating DKD. Small studies have shown that Prostaglandin E1 (PGE1) can improve renal blood circulation and decrease proteinuria and albuminuria.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-03-25 11:03:40 +1100" MODIFIED_BY="Narelle S Willis">
<P>To assess the benefits and harms of PGE1 for preventing the progression of DKD.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-03-02 17:11:23 +1100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Chinese Biomedicine Database (CBM) and reference lists of articles with no language restriction.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-03-16 17:09:09 +1100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials (RCTs) or quasi-RCTs comparing any PGE1 agent used for preventing the progression of DKD, regardless of dosage, mode of administration, addition of cointerventions or duration of treatment.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-03-16 22:35:26 +1100" MODIFIED_BY="[Empty name]">
<P>Two authors independently assessed study quality and extracted data. For dichotomous outcomes (all-cause mortality, ESKD), results were expressed as relative risk (RR) with 95% confidence intervals (CI). Continuous outcomes (microalbuminuria, proteinuria, albuminuria, doubling of serum creatinine, serum creatinine) were expressed as mean difference (MD) with 95% CI.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-03-16 22:36:34 +1100" MODIFIED_BY="[Empty name]">
<P>Six studies (271 patients) were included. Five studies investigated PGE1 with or without fosinopril/losartan versus fosinopril/losartan or no treatment and one compared PGE1 versus Xueshuantong (a Chinese medicinal herb). There was a significant decrease in urinary albumin excretion rate (UAER) in patients treated with PGE1 (MD -48.28 µg/min, 95% CI -75.29 to -21.28), other outcomes also showed a significant decrease in the patients with PGE1 (albuminuria: MD -143.66 mg/24 h, 95% CI -221.48 to -65.84; proteinuria: MD -300 g/24 h, 95% CI -518.34 to -81.66). PGE1 had a positive effect on albuminuria (MD -660 mg/24 h, 95% CI -867.07 to -452.93) in clinical DKD (CDN, III stage of DN) compared with Xueshuantong. No data on incidence of ESKD, all-cause mortality or quality of life were available.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-03-16 16:40:36 +1100" MODIFIED_BY="[Empty name]">
<P>PGE1 may have positive effects on DKD by reducing UAER, decreasing albuminuria and lessening proteinuria, with no obvious serious adverse events. However, limited by the poor methodological quality of the included studies and the small number of participants, there is currently insufficient evidence for determining if PGE1 could be used for preventing the progression of DKD. Large, properly randomised, placebo-controlled, double-blind studies are urgently needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-03-25 11:06:50 +1100" MODIFIED_BY="Narelle S Willis">
<BACKGROUND MODIFIED="2010-03-25 11:05:24 +1100" MODIFIED_BY="Narelle S Willis">
<CONDITION MODIFIED="2010-03-25 11:05:24 +1100" MODIFIED_BY="Narelle S Willis">
<P>Each year in the United States, more than 100,000 people are diagnosed with end-stage-kidney disease (ESKD). In many countries diabetes mellitus is the leading cause of ESKD and diabetic kidney disease (DKD) and has emerged as a silent epidemic worldwide, occurring in about 40% of diabetic patients. On the basis of recent reports (<LINK REF="REF-ADA-1997" TYPE="REFERENCE">ADA 1997</LINK>; <LINK REF="REF-Collins-2005" TYPE="REFERENCE">Collins 2005</LINK>; <LINK REF="REF-Gross-2005" TYPE="REFERENCE">Gross 2005</LINK>; <LINK REF="REF-Mitch-2004" TYPE="REFERENCE">Mitch 2004</LINK>), there has been a continuous increase in the incidence of DKD due to the much greater prevalence of type 2 diabetes in adults over the age of 40, resulting in the increased incidence of ESKD. Medicare costs associated with ESKD are projected to increase from US$12.7 billion in 1999 to US$28.0 billion in 2010. In China, DKD is particularly common among the elderly, and there is a similar incidence in other developing countries (<LINK REF="REF-Wu-2005" TYPE="REFERENCE">Wu 2005</LINK>).</P>
<P>DKD is one of the major microvascular complications of diabetes mellitus. It is commonly assumed that type 1 and type 2 diabetics have similar pathogenic kidney damage, and recent studies suggest a multifactorial pathogenesis of DKD. A number of potential mechanisms for kidney damage in diabetes have been identified (<LINK REF="REF-Brownlee-2001" TYPE="REFERENCE">Brownlee 2001</LINK>; <LINK REF="REF-Kanwar-2005" TYPE="REFERENCE">Kanwar 2005</LINK>; <LINK REF="REF-Molitch-2004" TYPE="REFERENCE">Molitch 2004</LINK>; <LINK REF="REF-Srivastava-2005" TYPE="REFERENCE">Srivastava 2005</LINK>; <LINK REF="REF-Yashpal-2005" TYPE="REFERENCE">Yashpal 2005</LINK>), These include:<BR/>
</P>
<UL>
<LI>Increased polyol pathway flux, resulting in the production of sorbitol by aldose reductase in the kidney. An increase in intracellular sorbitol results in depletion of intracellular myoinositol, the reduction of Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase activity.</LI>
<LI>Increased advanced glycation end-product formation and their extra- and intracellular effects play an important role in the thickening of the glomerular basement membrane, mesangial expansion and proliferation, and haemodynamic changes.</LI>
<LI>Hyperglycaemia increases the activity of protein kinase C in vascular smooth muscle and endothelial cells, which also contribute to DKD.</LI>
<LI>Increased hexosamine pathway flux.</LI>
<LI>Hypertension contributes to the development of DKD through associated glomerular hypertension. Haemodynamic factors alter the function of glomerular, mesangial, and epithelial cells, resulting in an increase in mesangial matrix formation and basement membrane thickening.</LI>
<LI>Hyperglycaemia leads to kidney disease via several mechanisms, including hypertrophy, increased endothelial cell permeability, and increased matrix protein synthesis.</LI>
<LI>Afferent arteriolar vasodilation and increased renal blood flow and glomerular capillary pressure from hyperglycaemia and other cytokines (e.g. prostaglandin, insulin-like growth factor, angiotensin II, nitric oxide).</LI>
<LI>Reactive oxygen species may activate intracellular signalling pathways leading to the activation of redox-sensitive transcription factors.</LI>
</UL>
<P>Drug treatment for DKD varies depending on the stage of disease. Early in the course of diabetes primary treatment focuses on intensive control optimising glucose, especially in patients with hypertension. Strict glucose control is recommended for patients with microalbuminuria and angiotensin-converting enzyme inhibitors (ACEi) are effective interventions for incipient or established DKD. ACEi appears to have special values with benefits, such as retarding proteinuria, that are independent of their blood pressure (BP)-lowering effect. Once kidney disease becomes evident, aggressive efforts at glucose control have marginal value. Reducing hypertension and intraglomerular pressure with ACEi alone remains the only proven means of slowing progression. Angiotensin II -receptor blockers (ARB) and calcium channel blockers (CCB) are being evaluated in clinical studies (<LINK REF="REF-Brenner-2001" TYPE="REFERENCE">Brenner 2001</LINK>; <LINK REF="REF-MICRO_x002d_HOPE-2000" TYPE="REFERENCE">MICRO-HOPE 2000</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-03-17 11:31:02 +1100" MODIFIED_BY="[Empty name]">
<P>Prostaglandin E1 (PGE1, alprostadil) belongs to the family of eicosanoids, which includes prostaglandins, thromboxanes, leukotrienes, lipoxins, hydroxyeicosatetraenoic acids and hepoxilins. The pharmacological roles of PGE1 include:<BR/>
</P>
<UL>
<LI>Modulates the enzyme adenylcyclase resulting in an increase in cAMP, which makes vascular smooth muscle relax (<LINK REF="REF-Paoletti-1986" TYPE="REFERENCE">Paoletti 1986</LINK>).</LI>
<LI>The depression of vascular reactivity protects vessels from the influence of catecholamines and angiotensin.</LI>
<LI>Inhibited the increased reactivity of the renin-aldosterone system, leading to the reduction of plasma renin activity and the plasma aldosterone concentration (<LINK REF="REF-Okada-1993" TYPE="REFERENCE">Okada 1993</LINK>).</LI>
<LI>Reduces plasma endothelin-1 concentration in patient with DKD (<LINK REF="REF-Itoh-2001" TYPE="REFERENCE">Itoh 2001</LINK>)</LI>
<LI>External PGE1 may modulate the urinary excretion ratio of PGF1 to thromboxane 2.</LI>
</UL>
</INTERVENTION>
<IMPORTANCE MODIFIED="2010-03-02 18:00:12 +1100" MODIFIED_BY="[Empty name]">
<P>Some clinical studies have demonstrated positive effects of PGE1 on delaying the progression of DKD (<LINK REF="REF-Ninomiya-1989" TYPE="REFERENCE">Ninomiya 1989</LINK>; <LINK REF="REF-Zhang-2002" TYPE="REFERENCE">Zhang 2002</LINK>), but a review of PGE1 for DKD has not yet been undertaken.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-03-17 11:31:25 +1100" MODIFIED_BY="[Empty name]">
<P>To assess the benefits and harms of PGE1 in preventing the progression of DKD.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-03-25 11:04:52 +1100" MODIFIED_BY="Narelle S Willis">
<SELECTION_CRITERIA MODIFIED="2010-03-25 11:04:52 +1100" MODIFIED_BY="Narelle S Willis">
<CRIT_STUDIES MODIFIED="2010-03-02 18:00:16 +1100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials (RCT) and quasi-RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) were eligible for this review. Studies published in any language were included. All identified studies, published or unpublished were investigated. If the required information was not available for analysis from the publication, the authors were contacted for the necessary details.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-03-17 11:32:53 +1100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<UL>
<LI>Diagnosis of diabetes confirmed according to the American Diabetes Association (<LINK REF="REF-ADA-1997" TYPE="REFERENCE">ADA 1997</LINK>) and WHO (<LINK REF="REF-WHO-1999" TYPE="REFERENCE">WHO 1999</LINK>).</LI>
<LI>Diagnosis and stage DKD based on the urine albumin excretion rate (UAER) and albumin excretion rate (AER) (<LINK REF="REF-Mogensen-1983" TYPE="REFERENCE">Mogensen 1983</LINK>).</LI>
<LI>Any type 1 or type 2 diabetic patients with DKD (e.g. micro- or macroalbuminuria).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<UL>
<LI>Kidney damage due to diseases other than diabetes.</LI>
<LI>Kidney damage due to diabetes other than type 1 or type 2 diabetes (e.g. gestational diabetes).</LI>
<LI>The final stage of DKD or ESKD were excluded.</LI>
</UL>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-03-25 11:04:52 +1100" MODIFIED_BY="Narelle S Willis">
<P>Any PGE1 agent used for preventing the progression of DKD, regardless of dosage, mode of administration or duration of treatment. The comparisons were to be:<BR/>
</P>
<UL>
<LI>PGE1 + routine treatment versus placebo + routine treatment</LI>
<LI>PGE1 + routine treatment versus routine treatment</LI>
<LI>PGE1 + routine treatment versus other drug + routine treatment</LI>
</UL>
<P>Routine treatment could include: glycaemic control, BP control and dietary control (such as protein restriction, sodium and phosphate restriction).</P>
<P>Other drugs could include: ACEi, ARB, CCB, Chinese herbal medicines.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-03-07 13:34:40 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Incidence of ESKD for patients with DKD at the end of treatment and follow-up.</LI>
<LI>Change in UAER (mg albumin/mmol creatinine), high and low microalbuminuria (mg/24 h, &#956;g/min) at the end of treatment and follow-up.</LI>
<LI>Changes in kidney function measures (e.g. creatinine clearance (CrCl) or doubling of serum creatinine (SCr) (mg/dL, &#956;mol/L); SCr (mg/dL, &#956;mol/L), proteinuria (mg/24 h), glomerular filtration rate (GFR) (mL/min)) at the end of the treatment and follow-up.</LI>
<LI>All-cause mortality.</LI>
<LI>Quality of life measured by any scale.</LI>
<LI>Other outcomes (e.g. glycaemic control (HbA1c%), plasma fibrinogen (ng/mL), change in BP (mm Hg), presence/absence of cardiovascular impairment (myocardial infarction, left ventricular dilatation, left ventricular hypertrophy).</LI>
<LI>Side effects of PGE1 (e.g. palpitation, headache, stomach ache, diarrhoea, nausea, allergic reactions, urticaria, anaphylaxis, ulceration at the injection site).</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-03-17 11:36:43 +1100" MODIFIED_BY="[Empty name]">
<P>We searched the following resources without language restriction.</P>
<ELECTRONIC_SEARCHES MODIFIED="2010-03-17 11:35:02 +1100" MODIFIED_BY="[Empty name]">
<P>Search strategies were developed with the assistance of the Cochrane Renal Group Trials Search Coordinators. Relevant studies were obtained from the following sources.</P>
<OL>
<LI>The Cochrane Renal Group's Specialised Register and the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library. </I>CENTRAL and the Renal Group's specialised register contain the handsearched results of conference proceedings from general and speciality meetings. This is an ongoing activity across the Cochrane Collaboration and is both retrospective and prospective (<LINK REF="REF-Master-List-2010" TYPE="REFERENCE">Master List 2010</LINK>). Therefore we will not specifically search conference proceedings. Please refer to The Cochrane Renal Review Group's Module in <I>The Cochrane Library</I> for the most up-to-date list of conference proceedings (<LINK REF="REF-Renal-Group-2010" TYPE="REFERENCE">Renal Group 2010</LINK>).</LI>
<LI>MEDLINE (from 1950) using the optimally sensitive strategy developed for the Cochrane Collaboration for the identification of RCTs (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>) with a specific search strategy developed with input from the Trial Search Coordinator.</LI>
<LI>EMBASE (from 1980) using a search strategy adapted from that developed for the Cochrane Collaboration for the identification of RCTs (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>) together with a specific search strategy developed with input from the Trial Search Coordinator.</LI>
<LI>We searched RCTs in CBM according to a modified MEDLINE search method (<LINK REF="REF-Deng-2008" TYPE="REFERENCE">Deng 2008</LINK>).</LI>
<LI>We searched for ongoing studies in the Clinical Trials, Chinese Clinical Trial Register and Current controlled trials.</LI>
</OL>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for search terms used.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-03-17 11:36:43 +1100" MODIFIED_BY="[Empty name]">
<OL>
<LI>References of published studies to identify additional studies.</LI>
<LI>We contacted study authors from China (only one study was undertaken in another country) to identify any published or unpublished papers and also contacted a pharmaceutical company (Taide Company in Beijing) who produced relevant products.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-03-17 12:01:17 +1100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2010-03-17 11:37:42 +1100" MODIFIED_BY="[Empty name]">
<P>The search strategy described was used to obtain titles and abstracts of studies that may have been relevant to this review. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable. Studies and reviews that might include relevant data or information on studies were retained initially.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-03-17 11:38:35 +1100" MODIFIED_BY="[Empty name]">
<P>Two authors independently assessed retrieved abstracts and, if necessary the full text, to determine which studies satisfied the inclusion criteria. Data extraction was carried out by the same authors independently using standard data extraction forms. Studies reported in non-English language journals were to be translated before assessment. Where more than one publication of one study existed, reports were grouped together and the most recent or most complete data set was used. Any discrepancy between published versions was highlighted</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-03-02 16:49:56 +1100" MODIFIED_BY="[Empty name]">
<P>The quality of included studies was assessed independently by two authors without blinding to authorship or journal using the checklist developed by the Cochrane Renal Group. Discrepancies were resolved by discussion. The quality items to be assessed were:</P>
<UL>
<LI>Randomisation methods</LI>
<LI>Allocation concealment</LI>
<LI>Blinding (participants, investigators, outcome assessors and data analysis)</LI>
<LI>Intention-to-treat analysis</LI>
<LI>Completeness of follow-up.</LI>
</UL>
<P>See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> for assessment criteria.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-03-17 11:39:17 +1100" MODIFIED_BY="[Empty name]">
<P>For dichotomous outcomes (e.g. all-cause mortality, ESKD) results were expressed as RR with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (e.g. CrCl, SCr, albuminuria), the mean difference (MD) was used, or the standardised mean difference (SMD) if different scales were used.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2010-03-17 12:01:17 +1100" MODIFIED_BY="[Empty name]">
<P>Any further information required from the original authors were requested by written correspondence or phone, and any relevant information obtained in this manner were included in the review. Disagreements were resolved in consultation.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-03-17 11:40:18 +1100" MODIFIED_BY="[Empty name]">
<P>Heterogeneity was analysed using a Chi² test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-03-02 17:01:17 +1100" MODIFIED_BY="[Empty name]">
<P>If enough studies were identified, funnel plots were to be used to investigate reporting biases (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-03-17 11:40:51 +1100" MODIFIED_BY="[Empty name]">
<P>Data were pooled using the random effects model but the fixed effects model was analysed to ensure robustness of the model chosen and susceptibility to outliers.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-03-16 17:44:22 +1100" MODIFIED_BY="[Empty name]">
<P>Subgroup analysis was used to explore possible sources of heterogeneity (e.g. participants, treatments and study quality). Heterogeneity among participants could be related to age, type or stage of diabetes mellitus. Heterogeneity in treatments could be related to prior agents used and the dose and duration of therapy. Heterogeneity among studies could be related to study quality. Adverse reactions were to be tabulated and assessed with descriptive techniques, as they were likely to be different for the various agents used. Where possible, the risk difference (RD) with 95% CI were to be calculated for each side effect, either compared to no treatment or to another agent.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-03-25 11:06:50 +1100" MODIFIED_BY="Narelle S Willis">
<STUDY_DESCRIPTION MODIFIED="2010-03-25 11:06:50 +1100" MODIFIED_BY="Narelle S Willis">
<SEARCH_RESULTS MODIFIED="2010-03-07 14:07:51 +1100" MODIFIED_BY="[Empty name]">
<P>A total of 68 studies claiming to be RCTs were identified (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>), one published in Japanese and the others in Chinese.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-03-25 11:06:50 +1100" MODIFIED_BY="Narelle S Willis">
<P>Six studies were included (<LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK>; <LINK REF="STD-Ma-2001" TYPE="STUDY">Ma 2001</LINK>; <LINK REF="STD-Sun-2007" TYPE="STUDY">Sun 2007</LINK>; <LINK REF="STD-Tan-2004" TYPE="STUDY">Tan 2004</LINK>; <LINK REF="STD-Yan-2002" TYPE="STUDY">Yan 2002</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>). We were unable to contact the authors for further information. All the studies were conducted in China, a total of 271 patients were analysed in this review, and all studies were classified into two comparisons based on the agents used in control group. Five studies compared PGE1 with or without ACEi/ARB versus ACEi/ARB or no treatment and one compared PGE1 versus Xueshuantong. The outcomes, including UAER, albuminuria, proteinuria, SCr and changes in BP, were assessed at the end of the intervention period in five studies and one study assessed outcomes at the end of an eight week follow-up period (<LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK>).</P>
<UL>
<LI>
<LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK> compared PGE1 (20 &#956;g/d) plus fosinopril (10 mg/d) with fosinopril (10 mg/d) for 28 days. The study included 86 inpatients with incipient and clinical DKD; the follow-up time was eight weeks. The control group received fosinopril, dietary control and glycaemic control, the treatment group received PGE1 in addition to the drugs the control group received.</LI>
<LI>
<LINK REF="STD-Ma-2001" TYPE="STUDY">Ma 2001</LINK> compared PGE1 (150 &#956;g/d) with no treatment. The study included 40 inpatients with clinical DKD. The study did not describe the baseline characteristics of the two groups. The control group received dietary control and glycaemic control, the treatment group received PGE1 in addition to the drugs the control group received. ACEi or ARB were not used in either group. Vasculitis at the injection site in treatment group was reported in three cases.</LI>
<LI>
<LINK REF="STD-Sun-2007" TYPE="STUDY">Sun 2007</LINK> compared PGE1 (20 &#956;g/d) plus losartan (100 mg/d) with losartan (100 mg/d) for 28 days. The study included 52 inpatients with DKD. The control group received losartan, dietary control and glycaemic control, the treatment group received PGE1 in addition to the drugs the control group received.</LI>
<LI>
<LINK REF="STD-Tan-2004" TYPE="STUDY">Tan 2004</LINK> compared PGE1 (10 &#956;g/d) with no treatment for three weeks. The study included 22 inpatients with DKD. The study did not describe the baseline characteristics of the two groups. The control group received dietary control and glycaemic control, the treatment group received PGE1 in addition to the drugs the control group received. ACEi or ARB were not used in either group.</LI>
<LI>
<LINK REF="STD-Yan-2002" TYPE="STUDY">Yan 2002</LINK> compared PGE1 (10 &#956;g/d) with no treatment for 4 weeks. The study included 71 inpatients with incipient and clinical DKD. The control group received exercise, dietary control and glycaemic control, the treatment group received PGE1 in addition to the drugs the control group received. ACEi or ARB were not used in either group. Two cases of vasculitis at the injection site in treatment group were reported.</LI>
<LI>
<LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK> compared PGE1 (10 &#956;g/d) with Xueshuantong (450 mg/d) for two weeks. The study included 82 inpatients with clinical DKD. The control group received ACEi or ARB, dietary control and glycaemic control, the treatment group received PGE1 in addition to the drugs the control group received. Two cases of pain and oedema at the injection site in treatment group were reported.</LI>
</UL>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-03-17 11:59:48 +1100" MODIFIED_BY="[Empty name]">
<P>Studies were excluded after assessing the abstract and full-text, and authors of the others were contacted. Several authors misunderstood true random allocation or authors summarized past medical records. Reasons for exclusion were:</P>
<UL>
<LI>Error in randomisation method (<LINK REF="STD-Zhao-2006b" TYPE="STUDY">Zhao 2006b</LINK>).</LI>
<LI>Before-after study (<LINK REF="STD-Lai-2005" TYPE="STUDY">Lai 2005</LINK>; <LINK REF="STD-Qin-2002" TYPE="STUDY">Qin 2002</LINK>).</LI>
<LI>Not an RCT (<LINK REF="STD-Li-2000" TYPE="STUDY">Li 2000</LINK>; <LINK REF="STD-Wang-2005b" TYPE="STUDY">Wang 2005b</LINK>; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>).</LI>
<LI>Authors summarized past medical records (<LINK REF="STD-Cao-2007" TYPE="STUDY">Cao 2007</LINK>; <LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>; <LINK REF="STD-Liu-2006a" TYPE="STUDY">Liu 2006a</LINK>; <LINK REF="STD-Sun-2006" TYPE="STUDY">Sun 2006</LINK>; <LINK REF="STD-Yang-2006" TYPE="STUDY">Yang 2006</LINK>; <LINK REF="STD-Zhang-2005" TYPE="STUDY">Zhang 2005</LINK>; <LINK REF="STD-Zhang-2006" TYPE="STUDY">Zhang 2006</LINK>; <LINK REF="STD-Zhong-2005" TYPE="STUDY">Zhong 2005</LINK>; <LINK REF="STD-Zhou-2006" TYPE="STUDY">Zhou 2006</LINK>).</LI>
<LI>Author refused further information (<LINK REF="STD-Huang-2007" TYPE="STUDY">Huang 2007</LINK>; <LINK REF="STD-Liao-2006" TYPE="STUDY">Liao 2006</LINK>; <LINK REF="STD-Xu-2005" TYPE="STUDY">Xu 2005</LINK>; <LINK REF="STD-Yu-2007" TYPE="STUDY">Yu 2007</LINK>; <LINK REF="STD-Zhao-2006a" TYPE="STUDY">Zhao 2006a</LINK>; <LINK REF="STD-Zhao-2007a" TYPE="STUDY">Zhao 2007a</LINK>; <LINK REF="STD-Zheng-2006" TYPE="STUDY">Zheng 2006</LINK>).</LI>
<LI>Error in data or wrong stage of DKD (<LINK REF="STD-Huang-2003" TYPE="STUDY">Huang 2003</LINK>; <LINK REF="STD-Wang-2005a" TYPE="STUDY">Wang 2005a</LINK>; <LINK REF="STD-Xie-2006" TYPE="STUDY">Xie 2006</LINK>; <LINK REF="STD-Xiong-2003" TYPE="STUDY">Xiong 2003</LINK>; <LINK REF="STD-Yang-2007b" TYPE="STUDY">Yang 2007b</LINK>; <LINK REF="STD-Zhu-2007" TYPE="STUDY">Zhu 2007</LINK>).</LI>
<LI>Participants were divided into groups at the author's discretion (<LINK REF="STD-Gao-2001" TYPE="STUDY">Gao 2001</LINK>; <LINK REF="STD-Gan-2007" TYPE="STUDY">Gan 2007</LINK>; <LINK REF="STD-Hu-2004" TYPE="STUDY">Hu 2004</LINK>; <LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>; <LINK REF="STD-Jiang-2006" TYPE="STUDY">Jiang 2006</LINK>; <LINK REF="STD-Li-2003" TYPE="STUDY">Li 2003</LINK>; <LINK REF="STD-Liu-2006b" TYPE="STUDY">Liu 2006b</LINK>; <LINK REF="STD-Liu-2007a" TYPE="STUDY">Liu 2007a</LINK>; <LINK REF="STD-Liu-2007b" TYPE="STUDY">Liu 2007b</LINK>; <LINK REF="STD-Niu-2007" TYPE="STUDY">Niu 2007</LINK>; <LINK REF="STD-Tang-2005" TYPE="STUDY">Tang 2005</LINK>; <LINK REF="STD-Wang-2004b" TYPE="STUDY">Wang 2004b</LINK>; <LINK REF="STD-Wang-2005c" TYPE="STUDY">Wang 2005c</LINK>; <LINK REF="STD-Xi-2007" TYPE="STUDY">Xi 2007</LINK>; <LINK REF="STD-Yang-2007a" TYPE="STUDY">Yang 2007a</LINK>).</LI>
<LI>Unsuitable intervention (<LINK REF="STD-Cui-2006" TYPE="STUDY">Cui 2006</LINK>; <LINK REF="STD-Ge-2007" TYPE="STUDY">Ge 2007</LINK>; <LINK REF="STD-Guo-2006" TYPE="STUDY">Guo 2006</LINK>; <LINK REF="STD-Jiao-2005" TYPE="STUDY">Jiao 2005</LINK>; <LINK REF="STD-Jiao-2007" TYPE="STUDY">Jiao 2007</LINK>; <LINK REF="STD-Li-2002" TYPE="STUDY">Li 2002</LINK>; <LINK REF="STD-Liu-2006c" TYPE="STUDY">Liu 2006c</LINK>; <LINK REF="STD-Meng-2003" TYPE="STUDY">Meng 2003</LINK>; <LINK REF="STD-Ninomiya-1989" TYPE="STUDY">Ninomiya 1989</LINK>; <LINK REF="STD-Shou-2007" TYPE="STUDY">Shou 2007</LINK>; <LINK REF="STD-Wang-2003" TYPE="STUDY">Wang 2003</LINK>; <LINK REF="STD-Wang-2004a" TYPE="STUDY">Wang 2004a</LINK>; <LINK REF="STD-Wang-2007a" TYPE="STUDY">Wang 2007a</LINK>; <LINK REF="STD-Wang-2007b" TYPE="STUDY">Wang 2007b</LINK>; <LINK REF="STD-Wu-2006" TYPE="STUDY">Wu 2006</LINK>; <LINK REF="STD-Xie-2002" TYPE="STUDY">Xie 2002</LINK>; <LINK REF="STD-Zhang-2004" TYPE="STUDY">Zhang 2004</LINK>; <LINK REF="STD-Zhao-2007b" TYPE="STUDY">Zhao 2007b</LINK>).</LI>
</UL>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-03-02 18:10:31 +1100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Method of randomisation</HEADING>
<P>All six studies stated that participants had been randomised, but no studies described the method of randomisation in detail.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>Allocation concealment was unclear in all included studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Study design</HEADING>
<P>All studies used parallel group design.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>Blinding was not mentioned in any of the included studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Completeness to follow-up</HEADING>
<P>There was no statement on intention-to-treat analysis in any of the included studies. No studies reported a sample size calculation.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-03-17 11:47:47 +1100" MODIFIED_BY="[Empty name]">
<P>No study compared PGE1 versus placebo, five studies compared PGE1 with or without fosinopril/losartan versus fosinopril/losartan or no treatment and one compared PGE1 versus Xueshuantong.</P>
<SUBSECTION>
<HEADING LEVEL="3">PGE1 + routine treatment versus routine treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Incidence of ESKD</HEADING>
<P>No studies evaluated incidence of ESKD.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Urinary albumin excretion rate</HEADING>
<P>Two studies involving 157 patients (<LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK>; <LINK REF="STD-Yan-2002" TYPE="STUDY">Yan 2002</LINK>) showed a positive effect on reducing UAER with pooled MD -48.28 µg/min (95% CI -75.29 to -21.28) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), with medium heterogeneity (I² = 37%, Chi² = 4.75 df = 3, P = 0.19). UAER was significantly lower for patients with incipient DKD (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.1 (76 patients): MD -39.12 µg/min, 95% CI -53.83 to -24.41; I² = 0%, Chi² = 0.31 df = 1, P = 0.58) and clinical DKD (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.2 (81 patients): MD -127.63 µg/min, 95% CI -215.63 to -39.63; I² = 0%, Chi² = 0.66 df = 1, P = 0.42), with no significant heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Albuminuria</HEADING>
<P>Albuminuria was assessed in two studies (<LINK REF="STD-Sun-2007" TYPE="STUDY">Sun 2007</LINK>; <LINK REF="STD-Tan-2004" TYPE="STUDY">Tan 2004</LINK>). There was a significant difference in albuminuria between PGE1 and no treatment (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> (74 patients): MD -143.66 mg/24 h, 95% CI -221.48 to -65.84), however there was significant heterogeneity (I² = 94%, Chi² = 17.92, df = 1, P &lt; 0.0001). </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Proteinuria</HEADING>
<P>
<LINK REF="STD-Ma-2001" TYPE="STUDY">Ma 2001</LINK> reported a significant decrease in proteinuria in the PGE1 group compared to the no treatment group (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> (40 patients): MD -300.00 g/24 h, 95% CI -518.34 to -81.66). </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Doubling of serum creatinine</HEADING>
<P>Doubling of SCr was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Serum creatinine</HEADING>
<P>The SCr was assessed in three studies (<LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK>; <LINK REF="STD-Ma-2001" TYPE="STUDY">Ma 2001</LINK>; <LINK REF="STD-Sun-2007" TYPE="STUDY">Sun 2007</LINK>). There was no significant difference in SCr between PGE1 and control (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK> (178 patients): MD -7.59 µmol/L, 95% CI -15.61 to 0.44), and there was significant heterogeneity (I² = 87%, Chi² = 23.25, df = 3, P &lt; 0.0001).</P>
<P>
<LINK REF="STD-Sun-2007" TYPE="STUDY">Sun 2007</LINK> reported no significant difference in SCr between PGE1 and no treatment in patients with DKD (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>.1 (52 patients): MD -1.50 µmol/L, 95% CI -6.56 to 3.56).</P>
<P>
<LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK> reported SCr in patients with incipient DKD. There was a significant decrease in SCr between PGE1 plus fosinopril and fosinopril after eight weeks follow-up in patients with incipient DKD (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>.2 (41 patients): MD -7.00 µmol/L, 95% CI -12.35 to -1.65).</P>
<P>The SCr of patients with clinical DKD was reported in two studies (<LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK>; <LINK REF="STD-Ma-2001" TYPE="STUDY">Ma 2001</LINK>). There was no significant difference in SCr between the two groups (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>.3 (85 patients): MD -10.95 µmol/L, 95% CI -25.63 to 3.72), and there was significant heterogeneity (I² = 88%, Chi² = 8.51, df = 1, P &lt; 0.004). </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">All-cause mortality</HEADING>
<P>All-cause mortality was not reported by any of the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life</HEADING>
<P>Quality of life was not reported by any of the studies. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood pressure</HEADING>
<P>Mean arterial pressure (MAP) of patients with incipient or clinical DKD was reported by <LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK>. There with no significant difference in MAP between the treatment and control groups (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK> (86 patients): MD -1.20 mm Hg, 95% CI -2.57 to 0.17), and there was no significant heterogeneity (I² = 0%, Chi² = 0.00, df = 1, P = 1). There was no significant difference for either those with incipient DKD (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>.1 (41 patients): MD -1.20 mm Hg, 95% CI -3.19 to 0.79) or clinical DKD (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>.2 (45 patients): MD -1.20 mm Hg, 95% CI -3.10 to 0.70) at the end of the treatment period.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">PGE1 + routine treatment versus Xueshuantong + routine treatment</HEADING>
<P>One study compared PGE1 + routine treatment with Xueshuantong + routine treatment (<LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Incidence of ESKD</HEADING>
<P>Incidence of ESKD was not reported. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Urinary albumin excretion rate</HEADING>
<P>UAER was not reported. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Proteinuria</HEADING>
<P>Proteinuria was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Albuminuria</HEADING>
<P>PGE1 reduced albuminuria compared with Xueshuantong (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> (82 patients): MD -660.00 mg/24 h, 95% CI -867.07 to -452.93).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Doubling of serum creatinine</HEADING>
<P>Doubling of SCr was not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Serum creatinine</HEADING>
<P>There was no significant difference in SCr at the end of the treatment period between PGE1 and Xueshuantong. (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> (82 patients): MD 1.00 µmol/L, 95% CI -2.28 to 4.28). </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">All-cause mortality</HEADING>
<P>All-cause mortality was not reported. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life</HEADING>
<P>Quality of life was not reported. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood pressure</HEADING>
<P>There was no significant difference at the end of the treatment period between PGE1 and Xueshuantong in systolic BP (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK> (82 patients): MD -3.00 mm Hg, 95% CI -9.52 to -3.52;) or diastolic BP (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK> (82 patients): MD -3.00 mm Hg, 95% CI -6.25 to 0.25).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse reactions</HEADING>
<P>Adverse events were reported in three studies (<LINK REF="STD-Ma-2001" TYPE="STUDY">Ma 2001</LINK>; <LINK REF="STD-Yan-2002" TYPE="STUDY">Yan 2002</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>), however they did not indicate whether the effects were ascertained through standardised monitoring or voluntary self-reporting.</P>
<SUBSECTION>
<HEADING LEVEL="4">PGE1 + routine treatment versus routine treatment</HEADING>
<P>
<LINK REF="STD-Ma-2001" TYPE="STUDY">Ma 2001</LINK> and <LINK REF="STD-Yan-2002" TYPE="STUDY">Yan 2002</LINK> described an occurrence of vasculitis in five patients at the injection site in the PGE1 group during the treatment period.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">PGE1 + routine treatment versus Xueshuantong + routine treatment</HEADING>
<P>
<LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK> reported pain and oedema at the injection site in two patients after 14 days in the PGE1 group.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-03-17 11:57:01 +1100" MODIFIED_BY="[Empty name]">
<P>This review evaluated the evidence for PGE1 for preventing the progression of DKD. Of the 68 initial studies identified, six studies (271 patients) met our inclusion criteria.</P>
<SUMMARY_OF_RESULTS MODIFIED="2010-03-17 11:54:45 +1100" MODIFIED_BY="[Empty name]">
<P>Based on the six small RCTs conducted in China, PGE1 may have a positive effect on reducing UAER, microalbuminuria and proteinuria in patients with DKD. None of the included studies reported the incidence of ESKD, all-cause mortality or quality of life. these results should be interpreted with caution because of the poor methodological quality of the included studies and the small numbers of participants. While the results of this review suggest PGE1 may exert a positive effect on DKD by reducing UAER, microalbuminuria and proteinuria, the recent reports show kidney function loss is not always linked to progression of urinary albumin excretion. Serum uric acid and components of the TNF-alfa pathway seem to be involved (<LINK REF="REF-Perkins-2009" TYPE="REFERENCE">Perkins 2009</LINK>; <LINK REF="REF-Rosolowsky-2008" TYPE="REFERENCE">Rosolowsky 2008</LINK>), so whether PGE1 prevented the progression of DKD remains unknown.</P>
<P>We undertook subgroup analyses comparing patients with different stages of DKD (incipient and clinical DKD). There were insufficient data to draw conclusions due to the poor methodological quality and the small sample size. For the other planned subgroups analyses of age, sex, type or duration of diabetic mellitus, treatment period and formulation of PGE1, differences in the included studies resulted in significant clinical heterogeneity and we were therefore could not investigate these subgroups.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-03-17 11:56:02 +1100" MODIFIED_BY="[Empty name]">
<P>All the included participants were Chinese and no data from other countries were available, therefore the present review is not representative of different racial or regional groups. Many potential confounding variables such as age, sex, stage of DKD and type or duration of diabetic mellitus were not reported in detail.</P>
<P>No study used placebo as a control; the Chinese herbal medicine Xueshuantong or no treatment were selected as the comparator. Routine therapy varied from study to study and included dietary control, blood sugar control and exercise with or without ACEi/ARB. The treatment period was short and differed between the studies. Only <LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK> reported an eight-week follow-up. The PGE1 used was produced by different pharmaceutical companies and different doses were used.</P>
<P>Reported outcomes focused on the improvements of laboratory indices, including UAER, albuminuria, proteinuria, SCr and BP in the short-term. Long-term outcomes such as progression to ESKD, all-cause mortality and health-related quality of life were not reported.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-03-17 11:57:01 +1100" MODIFIED_BY="[Empty name]">
<P>All the included studies were generally of poor quality. None described the randomisation procedure, method of blinding or the number of dropouts or withdrawals. Allocation concealment was unclear in all studies. The omission or non-reporting of these items may lead to or indicate selection, performance, attrition and detection bias which may contribute to false positive or negative findings. Authors failing to describe the method of randomisation may lead to selection bias. Unclear methods of blinding could result in performance, attrition and detection bias.</P>
<P>Xueshuantong is not standard treatment for DKD and there was no strong evidence from this review that it was effective. Because of the lack of blinding, participants may have been aware of the intervention they were receiving, and if they were aware that the treatment was not a standard treatment, patients may not adhere to the treatment protocol resulting in bias. In studies with a no treatment control group, participants were randomly assigned to no intervention, meaning neither the participants nor the investigators could be blinded. If allocation concealment was not adequate, RRs may be exaggerated and selection bias may occur. It is therefore plausible that PGE1 is truly ineffective and any apparent benefits are simply due to bias arising from the methodological weaknesses of the studies. No studies included in this systematic review reported a sample size calculation. Moreover, the small number of studies identified and their low methodological quality prohibited meaningful sensitivity analyses which were planned to investigate the robustness of the results of the review.</P>
<P>The pharmacotherapy for DKD requires a long-term strategy using drugs with few side effects. However all included studies were of short duration (the shortest course was 14 days) and most lacked follow-up data (only <LINK REF="STD-Lin-2004" TYPE="STUDY">Lin 2004</LINK> followed up at 8 weeks). Only three studies reported on serious adverse events (<LINK REF="STD-Ma-2001" TYPE="STUDY">Ma 2001</LINK>; <LINK REF="STD-Yan-2002" TYPE="STUDY">Yan 2002</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>), however they were in insufficient detail to analysis. According to the evidence of the review, it appeared that the adverse effects of PGE1 were trivial for the treatment of DKD, suggesting good tolerance of the PGE1 interventions overall. However, this is based on limited data. Therefore we cannot draw a conclusion on the safety of PGE1 agents, this will only be adequately quantified within large-scale clinical studies with long-term follow-up.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-03-16 17:41:06 +1100" MODIFIED_BY="[Empty name]">
<P>It was impossible to perform a funnel plot to investigate publication bias in this systematic review due to the small numbers of studies. All six included studies in this review were conducted in China and five published in Chinese, the remaining one published in both Chinese and English (abstract). <LINK REF="REF-Vickers1998" TYPE="REFERENCE">Vickers1998</LINK> found that in some countries, including China, positive results are more likely to be reported than negative studies, and tend to be published more quickly. Although we extensively searched for studies looking at the use of PGE1 for DKD, we cannot exclude the possibility that studies with negative findings remain unpublished.</P>
</POTENTIAL_BIASES>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-03-16 17:39:43 +1100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-03-10 17:10:25 +1100" MODIFIED_BY="[Empty name]">
<P>Based on this systematic review, PGE1 may have positive effects on DKD by reducing UAER, decreasing albuminuria and lessening proteinuria, with no obvious serious adverse events. However, limited by the poor methodological quality of the included studies and the small number of participants, there is currently insufficient evidence for determining if PGE1 could be used for preventing the progression of DKD.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-03-16 17:39:43 +1100" MODIFIED_BY="[Empty name]">
<P>Further research on PGE1 seems justified by both the claims of the doctors and the popularity of these therapies in general. Rigorously designed, multi-centre, randomised, double-blind, placebo-controlled studies are urgently needed in order to confirm (or refute) the available evidence of PGE1 use for preventing the progression of DKD. The following features should be addressed in future studies.</P>
<UL>
<LI>Standardised protocols need to be developed.</LI>
<LI>Randomisation and allocation concealment procedures should be reported in detail.</LI>
<LI>Application and clear description of blinding.</LI>
<LI>Baseline characteristics of the participants should be described in detail</LI>
<LI>Routine treatment in every group should be described in detail.</LI>
<LI>Outcome measures should not only include UAER, albuminuria, proteinuria, SCr and change of BP, but quality of life, incident of ESKD and mortality. The timing of outcome measures should also be described in detail. Outcomes for each stage of DKD (incipient DKD or clinical DKD) or total stage of DKD should be reported in detail.</LI>
<LI>Adverse events should be critically assessed by standardised monitoring or an effective self-report system and attention should be paid to long-term adverse effects.</LI>
<LI>Long-term follow-up is needed to evaluate the benefits and harms of PGE1.</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-03-17 11:57:28 +1100" MODIFIED_BY="[Empty name]">
<P>We would like to thank:</P>
<UL>
<LI>The referees of this review for their valuable comments and advice.</LI>
<LI>Gail Higgins for assistance in the development of search strategies.</LI>
<LI>Narelle Willis for her assistance as Managing Editor of the Cochrane Renal Group and editing of the review.</LI>
<LI>Wang Guihua, Fang Chengli, Tian Peng and Zhang Quanbo for data extraction and telephoning of study authors.</LI>
<LI>We would like to thank Drs Wu Hongmei, Li Jing and Liu Guanjian for their valuable comments and suggestions.</LI>
</UL>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-02-09 16:25:09 +1100" MODIFIED_BY="[Empty name]">
<P>None declared.<B>
<BR/>
</B>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-03-17 11:57:54 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Writing of protocol and review: JD, HW, JY, JL, YH</LI>
<LI>Screening of titles and abstracts: HW, JY</LI>
<LI>Assessment for inclusion: HW, JY</LI>
<LI>Quality assessment: HW, JY</LI>
<LI>Data extraction: HW, JY</LI>
<LI>Data entry into RevMan: HW, JY</LI>
<LI>Data analysis: JD, HW, JY, JL, YH</LI>
<LI>Disagreement resolution: JD, JL</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-04-27 22:50:01 +1000" MODIFIED_BY="[Empty name]"/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-03-17 12:32:55 +1100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-03-16 17:57:46 +1100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-03-02 17:28:13 +1100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2004" MODIFIED="2009-06-11 10:20:59 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Lin 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-06-11 10:20:59 +1000" MODIFIED_BY="Gail Y Higgins" NOTES="&lt;p&gt;Unable to locate this paper in MEDLINE, EMBASE or CENTRAL&lt;/p&gt;" NOTES_MODIFIED="2009-06-11 10:20:59 +1000" NOTES_MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin HC, Wu HL, Liu GH, Ruan XL, Ou BL, Zhang DW, et al</AU>
<TI>Treatment for diabetic nephropathy with integrated liposomal prostaglandin E1 and fosinopril</TI>
<SO>Chinese Journal of Practical Internal Medicine</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>9</NO>
<PG>538-40</PG>
<IDENTIFIERS MODIFIED="2009-06-11 10:20:59 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2001" MODIFIED="2009-06-11 10:15:26 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Ma 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-06-11 10:15:26 +1000" MODIFIED_BY="Gail Y Higgins" NOTES="&lt;p&gt;Unable to locate this paper in MEDLINE, EMBASE or CENTRAL&lt;/p&gt;" NOTES_MODIFIED="2009-06-11 10:15:26 +1000" NOTES_MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma S, Pan W, Shi Y</AU>
<TI>Effects of prostaglandin E1 on albuminuria of patients with diabetes mellitus</TI>
<SO>Clinical Medicine of China</SO>
<YR>2001</YR>
<VL>17</VL>
<NO>5</NO>
<PG>361-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2007" MODIFIED="2009-06-11 10:21:33 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Sun 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-06-11 10:21:33 +1000" MODIFIED_BY="Gail Y Higgins" NOTES="&lt;p&gt;Unable to locate this paper in MEDLINE, EMBASE or CENTRAL&lt;/p&gt;" NOTES_MODIFIED="2009-06-11 10:21:33 +1000" NOTES_MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun JP, Teng J, Xiao JH, Dong H</AU>
<TI>Combined therapy of PGE1 and losartan for proteinuria in patients with incipient diabetic nephropathy</TI>
<SO>Acta Academic Medicine Qingdao University</SO>
<YR>2007</YR>
<VL>43</VL>
<NO>6</NO>
<PG>503-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tan-2004" MODIFIED="2009-06-11 10:21:53 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Tan 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-06-11 10:21:53 +1000" MODIFIED_BY="Gail Y Higgins" NOTES="&lt;p&gt;Unable to locate this paper in MEDLINE, EMBASE or CENTRAL&lt;/p&gt;" NOTES_MODIFIED="2009-06-11 10:21:53 +1000" NOTES_MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tan YJ, An Z</AU>
<TI>Effect of Lipo-PGE1 injection on diabetic nephropathy and neuropathy</TI>
<SO>Journal of China-Japan Friendship Hospital</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>4</NO>
<PG>223-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yan-2002" MODIFIED="2009-06-11 10:22:20 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Yan 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-06-11 10:22:20 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yan WC, Ge W, Liang LQ</AU>
<TI>Clinical observation of the efficacy of lipo PGE1 in treating senile diabetic nephropathy</TI>
<SO>Practical Geriatrics</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>6</NO>
<PG>307-9</PG>
<IDENTIFIERS MODIFIED="2009-06-11 10:22:20 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2009-06-11 10:22:20 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00462024"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2007" MODIFIED="2010-03-02 17:28:13 +1100" MODIFIED_BY="[Empty name]" NAME="Zhang 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-06-11 10:22:36 +1000" MODIFIED_BY="Gail Y Higgins" NOTES="&lt;p&gt;Unable to locate this paper in MEDLINE, EMBASE or CENTRAL&lt;/p&gt;" NOTES_MODIFIED="2009-06-11 10:22:36 +1000" NOTES_MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang HJ, Kuang HY, Jiang XY, Sun H</AU>
<TI>Clinic observation on treatment of early diabetic nephropathy with Lipo PGE1</TI>
<SO>Journal of China-Japan Friendship Hospital</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>1</NO>
<PG>39,43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-03-16 17:57:46 +1100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Cao-2007" MODIFIED="2009-06-11 10:26:52 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Cao 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-06-11 10:26:52 +1000" MODIFIED_BY="Gail Y Higgins" NOTES="&lt;p&gt;Unable to locate this paper in MEDLINE, EMBASE or CENTRAL&lt;/p&gt;" NOTES_MODIFIED="2009-06-11 10:26:52 +1000" NOTES_MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao JZ</AU>
<TI>Curative analysis on treatment of diabetic nephropathy with Lipo PGE1, pancreatic kininogenase and fosinopril</TI>
<SO>Practical Pharmacy and Clinical Remedies</SO>
<YR>2007</YR>
<VL>10</VL>
<NO>5</NO>
<PG>283-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2006" MODIFIED="2009-06-11 10:27:29 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Chen 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-06-11 10:27:29 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen LB , Zhang CN , Zhao HY, Han J, Cui YF</AU>
<TI>Clinical observation of alprostadil to cure diabetic nephropathy</TI>
<SO>Journal of Medical Research</SO>
<YR>2006</YR>
<VL>35</VL>
<NO>6</NO>
<PG>25-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cui-2006" MODIFIED="2008-12-23 10:44:26 +1100" MODIFIED_BY="Narelle S Willis" NAME="Cui 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-28 18:45:23 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cui XF, Hu YH, Zhang YF, Zhou CH</AU>
<TI>Combination therapy of Lipo PGE1 with dipyridamole for diabetic nephropathy</TI>
<SO>Hebei Medical Journal</SO>
<YR>2006</YR>
<VL>28</VL>
<NO>10</NO>
<PG>931-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gan-2007" MODIFIED="2009-04-18 01:38:24 +1000" MODIFIED_BY="[Empty name]" NAME="Gan 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-04-18 01:38:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gan YQ</AU>
<TI>Analyses for the effects of the treatment for early diabetic nephropathy with integrated captopril and alprostadil</TI>
<SO>Chinese Medicine and Sanitation</SO>
<YR>2007</YR>
<VL>8</VL>
<NO>9</NO>
<PG>4-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gao-2001" MODIFIED="2009-06-11 10:28:24 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Gao 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-06-11 10:28:24 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gao L, Chang BC, Zhang Z</AU>
<TI>The curative effects of prostaglandin E1 (PGE1) and enalapril on diabetic nephropathy</TI>
<SO>Journal of Practical Diabetology</SO>
<YR>2001</YR>
<VL>9</VL>
<NO>3</NO>
<PG>25-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ge-2007" MODIFIED="2009-06-11 10:30:00 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Ge 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-06-11 10:30:00 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ge X</AU>
<TI>Early diabetic nephrosis treated with decoction nourishing Qi and kidney reducing turbid</TI>
<SO>Journal of Zhejiang University of Traditional Chinese Medicine</SO>
<YR>2007</YR>
<VL>31</VL>
<NO>4</NO>
<PG>443-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-2006" MODIFIED="2008-12-23 10:45:06 +1100" MODIFIED_BY="Narelle S Willis" NAME="Guo 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-17 15:16:03 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo SK</AU>
<TI>Combination therapy of Lipo PGE1 with herba erigerontis and fosinopril for diabetic nephropathy</TI>
<SO>Chinese Journal of Misdiagnostics</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>18</NO>
<PG>3555</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hu-2004" MODIFIED="2009-06-11 10:32:02 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Hu 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-06-11 10:32:02 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hu C, Chen PH, Zhou LF</AU>
<TI>Effect of alprostadil therapy on patients with diabetic nephropathy</TI>
<SO>Chinese Journal of Practical Medicine</SO>
<YR>2004</YR>
<VL>6</VL>
<NO>9</NO>
<PG>28-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2003" MODIFIED="2009-06-11 10:32:42 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Huang 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-06-11 10:32:42 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang ZD</AU>
<TI>The clinical observation of diabetic nephropathy treated by alprostadil</TI>
<SO>Modern Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>24</NO>
<PG>2656-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2005" MODIFIED="2009-06-11 10:33:54 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Huang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-11 10:33:54 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang XC, Xian XL</AU>
<TI>The comparative research on curative effect of alprostadil and lotensin on reducing albuminuria in early diabetic nephropathies</TI>
<SO>Central Plains Medical Journal</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>3</NO>
<PG>4-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2007" MODIFIED="2008-12-23 10:53:57 +1100" MODIFIED_BY="Narelle S Willis" NAME="Huang 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-11-13 02:13:11 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang YM</AU>
<TI>Combination therapy of Lipo PGE1 with DIZHIYA for diabetic nephropathy</TI>
<SO>Chinese Rural Medicine</SO>
<YR>2007</YR>
<VL>5</VL>
<NO>5</NO>
<PG>7-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-2006" MODIFIED="2009-06-11 10:34:10 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Jiang 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-06-11 10:34:10 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jiang WY</AU>
<TI>Clinical observation on therapeutic effect of Lipo PGE1 in treating early stage of diabetic nephropathic patients with proteinuria</TI>
<SO>Hainan Medical Journal</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>12</NO>
<PG>10-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiao-2005" MODIFIED="2008-12-23 10:46:14 +1100" MODIFIED_BY="Narelle S Willis" NAME="Jiao 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-28 18:48:12 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jiao J, Wang MZ, Gao F, Guo W, Zhang L, Li XF</AU>
<TI>A clinical review of combination of danshen and alprostadil to treat diabetic nephropathy</TI>
<SO>Journal of Xinjiang Medical University</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>9</NO>
<PG>847-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiao-2007" MODIFIED="2008-12-23 10:46:29 +1100" MODIFIED_BY="Narelle S Willis" NAME="Jiao 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-11-13 02:14:55 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jiao HB</AU>
<TI>Combination therapy of Huangqi with Lipo PGE1 for early diabetic nephropathy</TI>
<SO>Public Health</SO>
<YR>2007</YR>
<VL>10</VL>
<NO>1</NO>
<PG>29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lai-2005" MODIFIED="2009-06-11 10:36:02 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Lai 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-11 10:36:02 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lai JB</AU>
<TI>Clinical curative effect of alprostadil injection in the treatment of diabetic nephropathies</TI>
<SO>Northwest Pharmaceutical Journal</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>1</NO>
<PG>31-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2000" MODIFIED="2008-11-28 18:49:31 +1100" MODIFIED_BY="han wang" NAME="Li 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-11-28 18:49:31 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li WP, Liang KZ, Zhang BW, Huang Y, Li FX</AU>
<TI>A clinic observation of therapeutic effect of prostaglandin E1 in senile diabetic nephropathy</TI>
<SO>Hebei Medicine</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>7</NO>
<PG>598-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2002" MODIFIED="2008-11-13 00:51:49 +1100" MODIFIED_BY="han wang" NAME="Li 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-11-13 00:51:46 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li XY, Dou HM, Dong LK</AU>
<TI>Effect comparison of diabetic nephropathy treated by vein injection and vein infusion prostaglandin E1</TI>
<SO>Journal of Nurses Training</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>6</NO>
<PG>408-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2003" MODIFIED="2009-06-11 10:36:58 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Li 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-06-11 10:36:58 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li H, Lin YY, Zhen JQ</AU>
<TI>Effect of prostaglandin E1 therapy on patients with early diabetic nephropathy</TI>
<SO>Fujian Medical Journal</SO>
<YR>2003</YR>
<VL>25</VL>
<NO>1</NO>
<PG>125-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liao-2006" MODIFIED="2008-11-28 18:50:10 +1100" MODIFIED_BY="han wang" NAME="Liao 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-28 18:50:10 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liao ZR</AU>
<TI>Clinic observation on treatment of early diabetic nephropathy with Lipo PGE1</TI>
<SO>Journal of Chinese Clinical Medicine Research</SO>
<YR>2006</YR>
<VL>8</VL>
<NO>4</NO>
<PG>34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2006a" MODIFIED="2009-04-27 23:41:06 +1000" MODIFIED_BY="[Empty name]" NAME="Liu 2006a" YEAR="2006">
<REFERENCE MODIFIED="2009-04-18 01:39:19 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu XW, Ren W</AU>
<TI>Combination therapy of Lipo PGE1 with captopril for early diabetic nephropathy</TI>
<SO>Journal of Practical Diabetology</SO>
<YR>2006</YR>
<VL>2</VL>
<NO>2</NO>
<PG>25-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2006b" MODIFIED="2010-02-09 15:36:13 +1100" MODIFIED_BY="[Empty name]" NAME="Liu 2006b" YEAR="2006">
<REFERENCE MODIFIED="2010-02-09 15:36:13 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jin LY, Rao HP, Liu JH</AU>
<TI>Observation of the effect and nursing of patients of irbesartan with lipo PGE1 on treating early diabetic nephropathy</TI>
<SO>Journal of Nursing</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>3</NO>
<PG>76-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-13 01:49:39 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu JH</AU>
<TI>Combination therapy of Lipo PGE1 with irbesartan for early diabetic nephropathy</TI>
<SO>Journal of Practical Diabetology</SO>
<YR>2006</YR>
<VL>2</VL>
<NO>1</NO>
<PG>42-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2006c" MODIFIED="2009-06-11 10:37:41 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Liu 2006c" YEAR="2006">
<REFERENCE MODIFIED="2009-06-11 10:37:41 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu YC</AU>
<TI>Combination therapy of Lipo PGE1 with huangqi for diabetic nephropathy</TI>
<SO>Chinese Journal of Practical Medicine</SO>
<YR>2006</YR>
<VL>33</VL>
<NO>23</NO>
<PG>38-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2007a" MODIFIED="2008-11-13 02:18:35 +1100" MODIFIED_BY="han wang" NAME="Liu 2007a" YEAR="">
<REFERENCE MODIFIED="2008-11-13 02:18:34 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu JJ, Yu XM, Liu ZY</AU>
<TI>Effects of Lipo E1 on microalbuminuria and C-reactive protein of patients with early diabetes mellitus</TI>
<SO>Shandong Medical Journal</SO>
<YR>2007</YR>
<VL>47</VL>
<NO>25</NO>
<PG>66-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2007b" MODIFIED="2008-11-28 18:50:52 +1100" MODIFIED_BY="han wang" NAME="Liu 2007b" YEAR="">
<REFERENCE MODIFIED="2008-11-28 18:50:52 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu JJ, Chen W, Zhang JS, Pang H</AU>
<TI>The short-term therapeutic effect of Lipo PGE1 used in patients with early stage of diabetic nephropathy</TI>
<SO>Chinese Journal of Primary Medicine and Pharmacy</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>6</NO>
<PG>925-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meng-2003" MODIFIED="2008-12-23 10:47:05 +1100" MODIFIED_BY="Narelle S Willis" NAME="Meng 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-13 01:01:01 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meng HL, Lu BA, Ma XC</AU>
<TI>Treatment for diabetic nephropathy with integrated liposomal prostaglandin E1 and Lotensin</TI>
<SO>Clinical Medicine of China</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>10</NO>
<PG>919-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ninomiya-1989" MODIFIED="2010-03-16 17:57:46 +1100" MODIFIED_BY="[Empty name]" NAME="Ninomiya 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-03-16 17:57:46 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ninomiya Y, Arakawa M</AU>
<TI>Renal effects of prostaglandin E1 in type 2 (non-insulin-dependent) diabetic patients with subclinical nephropathy</TI>
<SO>Diabetes Research</SO>
<YR>1989</YR>
<VL>10</VL>
<NO>3</NO>
<PG>129-34</PG>
<IDENTIFIERS MODIFIED="2010-03-16 17:57:46 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-16 17:57:46 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="2680226"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niu-2007" MODIFIED="2009-06-11 10:38:16 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Niu 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-06-11 10:38:16 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu XF, Gan N, Kong YZ</AU>
<TI>Research of Lipo PGE1 therapy on patients with diabetic nephropathy</TI>
<SO>Journal of Medical Forum</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>20</NO>
<PG>44-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qin-2002" MODIFIED="2009-06-11 10:38:38 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Qin 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-06-11 10:38:38 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qin FY, Zhang L</AU>
<TI>The comparative research on curative effect of lipo PGE1 and ACEI on reducing albuminuria in early diabetic nephropathies</TI>
<SO>Journal of Dalian Medical University</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>3</NO>
<PG>184-6</PG>
<IDENTIFIERS MODIFIED="2008-11-13 23:35:41 +1100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shou-2007" MODIFIED="2009-06-11 10:38:51 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Shou 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-06-11 10:38:51 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shou ML, Yang AH, Zhang MS</AU>
<TI>Combination therapy of Lipo PGE1 with xueshuantong injection for diabetic nephropathy</TI>
<SO>Modern Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>30</NO>
<PG>4435-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2006" MODIFIED="2009-06-11 10:38:59 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Sun 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-06-11 10:38:59 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun LJ, Liu R, Lu D</AU>
<TI>Observation of lipo PGE1 effecting function of endothelial cells, fibrocystic activity and proteinuria in patients with diabetic nephropathy</TI>
<SO>Chinese Journal of Gerontology</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>8</NO>
<PG>1037-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2005" MODIFIED="2009-06-11 10:39:39 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Tang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-11 10:39:39 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang XL, Hong SJ</AU>
<TI>Effect of prostaglandin E1 lipid drug-loaded microcapsules on early diabetic nephropathy</TI>
<SO>China Pharmacy</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>23</NO>
<PG>1811-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2003" MODIFIED="2009-06-11 10:40:00 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Wang 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-06-11 10:40:00 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang QL, Lin XY, Gao W</AU>
<TI>Clinical observation on treatment of early diabetic nephropathy with traditional chinese and western medicine</TI>
<SO>Journal of Shandong Traditional Chinese Medicine</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>1</NO>
<PG>29-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2004a" MODIFIED="2009-06-11 10:40:15 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Wang 2004a" YEAR="2004">
<REFERENCE MODIFIED="2009-06-11 10:40:15 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J, Li ZN</AU>
<TI>Treatment of diabetic nephropathy with yiqi, yangyin, huoxue and alprostadil</TI>
<SO>Chinese Journal of Clinical Healthcare</SO>
<YR>2004</YR>
<VL>7</VL>
<NO>4</NO>
<PG>252-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2004b" MODIFIED="2009-06-11 10:40:32 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Wang 2004b" YEAR="2004">
<REFERENCE MODIFIED="2009-06-11 10:40:32 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang P, Zhong XW, Fu XQ, Cheng G</AU>
<TI>Effect of prostaglandin E1 therapy on patients with diabetic nephropathy</TI>
<SO>Sichuan Medical Journal</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>2</NO>
<PG>180-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005a" MODIFIED="2010-03-10 17:17:10 +1100" MODIFIED_BY="[Empty name]" NAME="Wang 2005a" YEAR="2005">
<REFERENCE MODIFIED="2010-03-10 17:17:10 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang B</AU>
<TI>Effects of prostaglandin E1 on microalbuminuria of patients with diabetes mellitus</TI>
<SO>Medical Journal of National Defending Forces in Southwest China</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>1</NO>
<PG>57-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005b" MODIFIED="2008-11-28 18:53:12 +1100" MODIFIED_BY="han wang" NAME="Wang 2005b" YEAR="2005">
<REFERENCE MODIFIED="2008-11-28 18:53:12 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang XJ</AU>
<TI>Clinical observation of liposomal prostaglandin E1 in treatment of diabetic nephropathic patients with proteinuria</TI>
<SO>Journal of Chinese Medical Theory and Practice</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>12</NO>
<PG>1760</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005c" MODIFIED="2008-11-13 01:31:14 +1100" MODIFIED_BY="han wang" NAME="Wang 2005c" YEAR="2005">
<REFERENCE MODIFIED="2008-11-13 01:31:12 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y</AU>
<TI>Combination therapy of lipo PGE1 with benazepril for early diabetic nephropathy</TI>
<SO>Chinese Journal of Practical Internal Medicine</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>2</NO>
<PG>139-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006" MODIFIED="2008-11-13 01:56:44 +1100" MODIFIED_BY="han wang" NAME="Wang 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-13 01:56:42 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang L, Zhao JR</AU>
<TI>Combination therapy of sodium ferulate with Lipo PGE1 for diabetic nephropathy</TI>
<SO>Journal of Practical Diabetology</SO>
<YR>2006</YR>
<VL>2</VL>
<NO>2</NO>
<PG>29-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2007a" MODIFIED="2009-06-11 10:41:01 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Wang 2007a" YEAR="2007">
<REFERENCE MODIFIED="2009-06-11 10:41:01 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang WX</AU>
<TI>Combination therapy of lipo PGE1 with irbesartan for diabetic nephropathy</TI>
<SO>Medical Journal of Communications</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>5</NO>
<PG>535-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2007b" MODIFIED="2009-06-11 10:41:08 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Wang 2007b" YEAR="2007">
<REFERENCE MODIFIED="2009-06-11 10:41:08 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang ZX, Wu RG, Tian SJ, Zhang XL</AU>
<TI>Combination therapy of low-molecular heparin sodium with lipo PGE1 for diabetic nephropathy</TI>
<SO>Chinese modern Medicine</SO>
<YR>2007</YR>
<VL>5</VL>
<NO>6</NO>
<PG>42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2006" MODIFIED="2009-06-11 10:41:18 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Wu 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-06-11 10:41:18 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu ZX</AU>
<TI>Combination therapy of lipo PGE1 with huangqi for early diabetic nephropathy</TI>
<SO>Modern Medicine and Health</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>11</NO>
<PG>1631-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xi-2007" MODIFIED="2009-06-11 10:41:29 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Xi 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-06-11 10:41:29 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xi ZR, Xu P</AU>
<TI>Combination therapy of benazepril with lipo PGE1 for diabetic nephropathy</TI>
<SO>Medical Journal of Communications</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>5</NO>
<PG>531,533</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xie-2002" MODIFIED="2009-06-11 10:42:02 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Xie 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-06-11 10:42:02 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xie BX, Zhang XF</AU>
<TI>Clinical study on the therapeutic effect of huangqi and PGE1 in the treatment of diabetic nephropathies</TI>
<SO>Journal of Traditional Chinese Medicine University of Hunan</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>3</NO>
<PG>52-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xie-2006" MODIFIED="2008-11-13 17:19:18 +1100" MODIFIED_BY="han wang" NAME="Xie 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-13 17:19:15 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xie H</AU>
<TI>Combination therapy of Lipo PGE1 with enalapril for early diabetic nephropathy</TI>
<SO>Journal of Chinese Integrated Traditional and Western Medicine</SO>
<YR>2006</YR>
<VL>4</VL>
<NO>10</NO>
<PG>57-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xiong-2003" MODIFIED="2009-06-11 10:42:22 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Xiong 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-06-11 10:42:22 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xiong XY</AU>
<TI>The clinical observation of diabetic nephropathy treated by alprostadil</TI>
<SO>Chongqing Medicine</SO>
<YR>2003</YR>
<VL>32</VL>
<NO>4</NO>
<PG>496-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2005" MODIFIED="2009-06-11 10:42:40 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Xu 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-11 10:42:40 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu GG, Wang YF, Lin YD</AU>
<TI>Curative observation on treatment of early diabetic nephropathy with lipo PGE1</TI>
<SO>Journal of Practical Medicine</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>3</NO>
<PG>309-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2006" MODIFIED="2008-11-13 01:59:41 +1100" MODIFIED_BY="han wang" NAME="Yang 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-13 01:59:39 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang L</AU>
<TI>Combination therapy of Lipo PGE1 with valsartan for early diabetic nephropathy</TI>
<SO>Journal of Chinese Practical Diagnosis and Therapy</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>12</NO>
<PG>889-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2007a" MODIFIED="2009-06-11 10:42:51 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Yang 2007a" YEAR="2007">
<REFERENCE MODIFIED="2009-06-11 10:42:51 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang P</AU>
<TI>Combination therapy of lipo PGE1 with benazepril for diabetic nephropathy</TI>
<SO>Journal of Community Medicine</SO>
<YR>2007</YR>
<VL>5</VL>
<NO>11S</NO>
<PG>30-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2007b" MODIFIED="2009-06-11 10:43:04 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Yang 2007b" YEAR="2007">
<REFERENCE MODIFIED="2009-06-11 10:43:04 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang ZL, Peng CX, Liu MX</AU>
<TI>Combination therapy of traditional chinese medicine with lipo PGE1 for diabetic nephropathy</TI>
<SO>Journal of Clinical Nephrology</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>5</NO>
<PG>201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2007" MODIFIED="2009-04-18 01:47:31 +1000" MODIFIED_BY="[Empty name]" NAME="Yu 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-04-18 01:47:31 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu H, Feng YX, Liu L, Chen LX, Zhang Y</AU>
<TI>Effects of lipo-prostaglandin E1 for patients with diabetic nephropathy</TI>
<SO>Chinese Journal of New Drugs</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>6</NO>
<PG>477-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2004" MODIFIED="2009-06-11 10:43:40 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Zhang 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-06-11 10:43:40 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang HL</AU>
<TI>The clinical investigation of diabetic nephropathy treated by PGE1 and huangqi Injection</TI>
<SO>Journal of Qinghai Medical College</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>3</NO>
<PG>190-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005" MODIFIED="2009-06-11 10:43:52 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Zhang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-11 10:43:52 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L, Shi JH, Chen MQ</AU>
<TI>Combination therapy of lipo PGE1 with losartan for early diabetic nephropathy</TI>
<SO>Journal of Practical Diabetology</SO>
<YR>2007</YR>
<VL>3</VL>
<NO>3</NO>
<PG>43-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-28 18:58:49 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang L, Shi JH, Chen MQ</AU>
<TI>Treatment of diabetic nephropathy with integrated liposomal prostaglandin E1 and benazepril</TI>
<SO>Chinese Journal of New Clinical Medicine</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>9</NO>
<PG>817-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2006" MODIFIED="2009-06-11 10:44:06 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Zhang 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-06-11 10:44:06 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang ZG, Hou JH</AU>
<TI>Clinical observation of prostaglandin injection and enalapril in treatment of diabetic nephropathy</TI>
<SO>Public Medical Forum Magazine</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>3</NO>
<PG>213-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2006a" MODIFIED="2008-12-23 10:56:30 +1100" MODIFIED_BY="Narelle S Willis" NAME="Zhao 2006a" YEAR="2006">
<REFERENCE MODIFIED="2008-11-13 02:01:42 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao L, Li L, Guo YJ</AU>
<TI>Treatment of diabetic nephropathy with integrated liposomal prostaglandin E1 and benazepril</TI>
<SO>Chinese Journal of Abdominal Diseases</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>3</NO>
<PG>165-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2006b" MODIFIED="2009-06-11 10:44:31 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Zhao 2006b" YEAR="2006">
<REFERENCE MODIFIED="2009-06-11 10:44:31 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao F</AU>
<TI>Therapeutic efficacy of irbesartan combined with alprostadil on early diabetic nephropathy</TI>
<SO>Qinghai Medical Journal</SO>
<YR>2006</YR>
<VL>36</VL>
<NO>11</NO>
<PG>7-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2007a" MODIFIED="2009-06-11 10:44:59 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Zhao 2007a" YEAR="2007">
<REFERENCE MODIFIED="2009-06-11 10:44:59 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao CJ , Liu JH , Tang W, Wang ZL</AU>
<TI>Clinical effects of prostaglandin E1 Injection combined With bailing capsule in treatment of diabetic nephropathy</TI>
<SO>Journal of Nanhua University (Medical Edition)</SO>
<YR>2007</YR>
<VL>35</VL>
<NO>4</NO>
<PG>591-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2007b" MODIFIED="2009-06-11 10:45:12 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Zhao 2007b" YEAR="2007">
<REFERENCE MODIFIED="2009-06-11 10:45:12 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao L, Lan LG, Min XL, Lu AH, Zhu XQ, He XL, et al</AU>
<TI>Integrated treatment of traditional Chinese medicine and western medicine for early-and intermediate-stage diabetic nephropathy</TI>
<SO>Journal of Southern Medical University</SO>
<YR>2007</YR>
<VL>27</VL>
<NO>7</NO>
<PG>1052-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-2006" MODIFIED="2008-11-13 02:05:03 +1100" MODIFIED_BY="han wang" NAME="Zheng 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-13 02:05:02 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng HZ, Lin LQ</AU>
<TI>Combination therapy of lipo PGE1 with Lotensin for early diabetic nephropathy</TI>
<SO>Heilongjiang Medical Journal</SO>
<YR>2006</YR>
<VL>30</VL>
<NO>10</NO>
<PG>770-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhong-2005" MODIFIED="2009-06-11 10:45:53 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Zhong 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-11 10:45:53 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhong XW, Liao ZH, Zhou JH, Xu CR</AU>
<TI>Treatment for diabetic nephropathy with Integrated liposomal prostaglandin E1 and benazepril</TI>
<SO>International Medicine &amp; Health Guidance News</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>4</NO>
<PG>29-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-28 19:02:39 +1100" MODIFIED_BY="han wang" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhong XW, Liao ZH, Zhou JH, Xu CR</AU>
<TI>Treatment for diabetic nephropathy with integrated liposomal prostaglandin E1 and benazepril</TI>
<SO>Modern Journal of Chinese Integrated Traditional Chinese and Western Medicine</SO>
<YR>2005</YR>
<VL>3</VL>
<NO>11</NO>
<PG>967-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2006" MODIFIED="2009-06-11 10:46:00 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Zhou 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-06-11 10:46:00 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou YH, Feng JH</AU>
<TI>Combination therapy of lipo PGE1 with benazepril for microalbuminuria induced by early diabetic nephropathy</TI>
<SO>Journal of North China Coal Medical College</SO>
<YR>2006</YR>
<VL>8</VL>
<NO>5</NO>
<PG>609-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2007" MODIFIED="2010-03-10 17:17:37 +1100" MODIFIED_BY="[Empty name]" NAME="Zhu 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-03-10 17:17:37 +1100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;none of the excluded studies could be found in MEDLINE, EMBASE or CENTRAL&lt;/p&gt;&lt;p&gt;the following studies from the register were sent to authors - these have not been dealt with in excluded studies&lt;/p&gt;&lt;p&gt;Wolf SC, Erley CM. Effects of prostaglandin E1 (PGE1) on proteinuria, glomerular permeability and renal haemodynamics in patients with chronic glomerulonephritis [abstract]. Nephrology Dialysis Transplantation 1994;9(7):902.&lt;br&gt;&lt;br&gt;Sun D, Feng JM, Zhao YL, Jin T, Wang LN. Effects of prostaglandin E1 on the progression of aristolochic acid nephropathy. Chinese Medical Sciences Journal 2005 Mar;20(1):67-9.&lt;br&gt;&lt;br&gt;Niwa T, Asada H, Yamada K. Prostaglandin E1 infusion therapy in chronic glomerulonephritis--a double-blind, crossover trial. Prostaglandins Leukotrienes &amp;amp; Medicine 1985 Sep;19(3):227-33.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-03-10 17:17:37 +1100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu KS , Yan YX , Wang P, Wang P, Qu JC, Yuan FY, Liu ZW</AU>
<TI>Clinical observation of Lipo prostaglandin E1 in treating exercise-induced microalbuminuria or microalbuminuria in aged patients with type 2 diabetes</TI>
<SO>Chinese Journal of Clinical Healthcare</SO>
<YR>2007</YR>
<VL>10</VL>
<NO>4</NO>
<PG>372-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-04-18 01:57:17 +1000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-03-17 12:32:55 +1100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-03-16 17:56:46 +1100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ADA-1997" MODIFIED="2009-04-28 01:17:33 +1000" MODIFIED_BY="[Empty name]" NAME="ADA 1997" TYPE="JOURNAL_ARTICLE">
<AU>American Diabetes Association</AU>
<TI>Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus</TI>
<SO>Diabetes Care</SO>
<YR>1997</YR>
<VL>20</VL>
<NO>7</NO>
<PG>1183-97</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9203460"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brenner-2001" MODIFIED="2010-03-16 17:56:00 +1100" MODIFIED_BY="[Empty name]" NAME="Brenner 2001" TYPE="JOURNAL_ARTICLE">
<AU>Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al</AU>
<TI>Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<NO>12</NO>
<PG>861-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11565518"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brownlee-2001" MODIFIED="2009-04-18 01:57:18 +1000" MODIFIED_BY="[Empty name]" NAME="Brownlee 2001" TYPE="JOURNAL_ARTICLE">
<AU>Brownlee M</AU>
<TI>Biochemistry and molecular cell biology of diabetic complications</TI>
<SO>Nature</SO>
<YR>2001</YR>
<VL>414</VL>
<NO>6865</NO>
<PG>813-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11742414"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Collins-2005" MODIFIED="2010-03-16 17:56:16 +1100" MODIFIED_BY="[Empty name]" NAME="Collins 2005" TYPE="JOURNAL_ARTICLE">
<AU>Collins AJ, Kasiske B, Herzog C, Chavers B, Foley R, Gilbertson D, et al</AU>
<TI>Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2005</YR>
<VL>45</VL>
<NO>1 Suppl 1</NO>
<PG>A5-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15640975"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Deng-2008" MODIFIED="2009-04-18 01:57:18 +1000" MODIFIED_BY="[Empty name]" NAME="Deng 2008" TYPE="BOOK">
<AU>Deng KG</AU>
<SO>The search and utilization of evidence from evidence-base medicine</SO>
<YR>2008</YR>
<PB>People heath publishing company</PB>
<CY>Chengdu</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gross-2005" MODIFIED="2009-04-18 01:57:18 +1000" MODIFIED_BY="[Empty name]" NAME="Gross 2005" TYPE="JOURNAL_ARTICLE">
<AU>Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T</AU>
<TI>Diabetic nephropathy: diagnosis, prevention, and treatment</TI>
<SO>Diabetes Care</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>1</NO>
<PG>164-76</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15616252"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2009-04-18 01:57:18 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-03-02 16:59:52 +1100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration. 2008. Available from www.cochrane-handbook.org</TI>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Itoh-2001" MODIFIED="2010-03-16 17:56:34 +1100" MODIFIED_BY="[Empty name]" NAME="Itoh 2001" TYPE="JOURNAL_ARTICLE">
<AU>Itoh Y, Yasui T, Kakizawa H, Makino M, Fujiwara K, Kato T, et al</AU>
<TI>The therapeutic effect of lipo PGE1 on diabetic neuropathy-changes in endothelin and various angiopathic factors</TI>
<SO>Prostaglandins &amp; Other Lipid Mediators</SO>
<YR>2001</YR>
<VL>66</VL>
<NO>3</NO>
<PG>221-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11577785"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kanwar-2005" MODIFIED="2010-03-16 17:56:46 +1100" MODIFIED_BY="[Empty name]" NAME="Kanwar 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kanwar YS, Akagi S, Sun L, Nayak B, Xie P, Wada J, et al</AU>
<TI>Cell biology of diabetic kidney disease</TI>
<SO>Nephron. Experimental Nephrology</SO>
<YR>2005</YR>
<VL>101</VL>
<NO>3</NO>
<PG>e100-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16088221"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2008" MODIFIED="2009-11-05 01:37:17 +1100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2008" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies. In Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0(updated February 2008)</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<YR>2008</YR>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Master-List-2010" MODIFIED="2010-02-09 16:06:05 +1100" MODIFIED_BY="[Empty name]" NAME="Master List 2010" TYPE="OTHER">
<AU>United States Cochrane Center</AU>
<TI>Master list of journals being searched</TI>
<SO>http://apps1.jhsph.edu/cochrane/masterlist.asp</SO>
<YR>(accessed February 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MICRO_x002d_HOPE-2000" MODIFIED="2009-04-28 02:03:40 +1000" MODIFIED_BY="[Empty name]" NAME="MICRO-HOPE 2000" TYPE="JOURNAL_ARTICLE">
<AU>Amonymous</AU>
<TI>Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub study. Heart Outcomes Prevention Evaluation Study Investigators</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<NO>9200</NO>
<PG>253-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10675071"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mitch-2004" MODIFIED="2009-04-18 01:57:18 +1000" MODIFIED_BY="[Empty name]" NAME="Mitch 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mitch WE</AU>
<TI>Treating diabetic nephropathy--are there only economic issues?</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>351</VL>
<NO>19</NO>
<PG>1934-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15516698"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mogensen-1983" MODIFIED="2005-06-02 14:00:03 +1000" MODIFIED_BY="[Empty name]" NAME="Mogensen 1983" TYPE="JOURNAL_ARTICLE">
<AU>Mogensen CE, Christensen CK, Vittinghus E</AU>
<TI>The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy</TI>
<SO>Diabetes</SO>
<YR>1983</YR>
<VL>32 Suppl 2</VL>
<PG>64-78</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6400670"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Molitch-2004" MODIFIED="2010-02-09 16:08:32 +1100" MODIFIED_BY="[Empty name]" NAME="Molitch 2004" TYPE="JOURNAL_ARTICLE">
<AU>Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, et al</AU>
<TI>Nephropathy in diabetes</TI>
<SO>Diabetes Care</SO>
<YR>2004</YR>
<VL>27 Suppl 1</VL>
<PG>S79-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14693934"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ninomiya-1989" MODIFIED="2009-04-18 01:57:18 +1000" MODIFIED_BY="[Empty name]" NAME="Ninomiya 1989" TYPE="JOURNAL_ARTICLE">
<AU>Ninomiya Y, Arakawa M</AU>
<TI>Renal effects of prostaglandin E1 in type 2 (non-insulin-dependent) diabetic patients with subclinical nephropathy</TI>
<SO>Diabetes Research</SO>
<YR>1889</YR>
<VL>10</VL>
<NO>3</NO>
<PG>129-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2680226"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Okada-1993" MODIFIED="2009-04-18 01:57:18 +1000" MODIFIED_BY="[Empty name]" NAME="Okada 1993" TYPE="JOURNAL_ARTICLE">
<AU>Okada S, Ichiki K, Tanokuchi S, Ishii K, Hamada H, Ota Z</AU>
<TI>Effect of prostaglandin E1 on the renin-aldosterone system in patients with diabetic nephropathy</TI>
<SO>Journal of International Medical Research</SO>
<YR>1993</YR>
<VL>21</VL>
<NO>3</NO>
<PG>126-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8299855"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Paoletti-1986" MODIFIED="2009-04-18 01:57:18 +1000" MODIFIED_BY="[Empty name]" NAME="Paoletti 1986" TYPE="BOOK_SECTION">
<AU>Paoletti R</AU>
<TI>Biochemistry and pharmacology of prostaglandin E1: introductory remarks</TI>
<SO>Prostaglandin E1 in atherosclerosis</SO>
<YR>1986</YR>
<VL>307</VL>
<ED>H. Sinzinger, W.Rogatti</ED>
<PB>Springer-Verlag</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perkins-2009" MODIFIED="2010-02-09 16:09:28 +1100" MODIFIED_BY="[Empty name]" NAME="Perkins 2009" TYPE="JOURNAL_ARTICLE">
<AU>Perkins BA, Krolewski AS</AU>
<TI>Early nephropathy in type 1 diabetes: the importance of early renal function decline</TI>
<SO>Current Opinion in Nephrology &amp; Hypertension</SO>
<YR>2009</YR>
<VL>18</VL>
<PG>233-40</PG>
<IDENTIFIERS MODIFIED="2010-02-09 16:09:28 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-02-09 16:09:28 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19300247"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Renal-Group-2010" MODIFIED="2010-03-02 17:00:48 +1100" MODIFIED_BY="[Empty name]" NAME="Renal Group 2010" TYPE="OTHER">
<AU>Willis NS, Mitchell R, Higgins GY, Webster AC, Craig JC</AU>
<TI>Cochrane Renal Group</TI>
<SO>About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2010, Issue 2. Art. No.: RENAL</SO>
<YR>(accessed February 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosolowsky-2008" MODIFIED="2010-02-09 16:06:34 +1100" MODIFIED_BY="[Empty name]" NAME="Rosolowsky 2008" TYPE="JOURNAL_ARTICLE">
<AU>Rosolowsky ER, Niewczas MA, Ficociello LH, Perkins BA, Warram JH, Krolewski AS</AU>
<TI>Between hyperfiltration and impairment: Demystifying early renal functional changes in diabetic nephropathy</TI>
<SO>Diabetes Reseach &amp; Clinical Practice</SO>
<YR>2008</YR>
<VL>82</VL>
<NO>Suppl 1</NO>
<PG>46-53</PG>
<IDENTIFIERS MODIFIED="2010-02-09 16:06:31 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-02-09 16:06:31 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18849087"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Srivastava-2005" MODIFIED="2009-04-18 01:57:18 +1000" MODIFIED_BY="[Empty name]" NAME="Srivastava 2005" TYPE="JOURNAL_ARTICLE">
<AU>Srivastava SK, Ramana KV, Bhatnagar A</AU>
<TI>Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options</TI>
<SO>Endocrine Reviews</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>3</NO>
<PG>380-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15814847"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vickers1998" MODIFIED="2010-02-09 16:07:31 +1100" MODIFIED_BY="[Empty name]" NAME="Vickers1998" TYPE="JOURNAL_ARTICLE">
<AU>Vickers A, Goyal N, Harland R, Rees R</AU>
<TI>Do certain countries produce only positive results? A systematic review of controlled trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>2</NO>
<PG>159-66</PG>
<IDENTIFIERS MODIFIED="2009-04-28 01:09:42 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-04-28 01:09:42 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9551280"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-1999" MODIFIED="2009-04-18 01:57:19 +1000" MODIFIED_BY="[Empty name]" NAME="WHO 1999" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Definition, diagnosis and classification of diabetes mellitus and its complications</TI>
<SO>http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf</SO>
<YR>(accessed September 2007)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-2005" MODIFIED="2010-02-09 16:07:41 +1100" MODIFIED_BY="[Empty name]" NAME="Wu 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wu AY, Kong NC, de Leon FA, Pan CY, Tai TY, Yeung VT, et al</AU>
<TI>An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study</TI>
<SO>Diabetologia</SO>
<YR>2005</YR>
<VL>48</VL>
<NO>1</NO>
<PG>17-26</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15616801"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yashpal-2005" MODIFIED="2009-04-28 02:03:56 +1000" MODIFIED_BY="[Empty name]" NAME="Yashpal 2005" TYPE="JOURNAL_ARTICLE">
<AU>Yashpal NK, Li J, Wheeler MB, Wang R</AU>
<TI>Expression of {beta}1 Integrin receptors during rat pancreas development--sites and dynamics</TI>
<SO>Endocrinology</SO>
<YR>2005</YR>
<VL>146</VL>
<NO>4</NO>
<PG>1798-807</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15618357"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2002" MODIFIED="2009-04-18 01:57:18 +1000" MODIFIED_BY="[Empty name]" NAME="Zhang 2002" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Z, Yu DM, Zhao W</AU>
<TI>Effect of prostaglandin E1 on proteinuria in the patients with diabetic nephropathy</TI>
<SO>Chinese Journal of Diabetes</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>5</NO>
<PG>276-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-03-17 12:32:55 +1100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Wang-2008" MODIFIED="2010-03-17 12:32:55 +1100" MODIFIED_BY="[Empty name]" NAME="Wang 2008" TYPE="COCHRANE_PROTOCOL">
<AU>Wang H, Deng JL, Yue J, Li J, Hou YB</AU>
<TI>Prostaglandin E1 for preventing the progression of diabetic kidney disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-03-17 12:32:49 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-03-17 12:32:49 +1100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006872"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-03-17 12:25:33 +1100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-03-17 12:25:27 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-03-02 17:39:27 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2004">
<CHAR_METHODS MODIFIED="2010-02-08 17:23:15 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Design: Controlled, parallel, RCT</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-09 15:22:39 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Country: China</LI>
<LI>DKD (stages III and IV), as per <LINK REF="REF-ADA-1997" TYPE="REFERENCE">ADA 1997</LINK>; <LINK REF="REF-Mogensen-1983" TYPE="REFERENCE">Mogensen 1983</LINK>
</LI>
<LI>Duration of DM: 12.7 ± 4.4 years</LI>
<LI>Age: 50.3 ± 9.6 years</LI>
<LI>Number (treatment/control): 42/44</LI>
</UL>
<P>
<B>Exclusion criteria</B>: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-08 17:30:07 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment group</B>
</P>
<UL>
<LI>PGE1 (20 &#956;g/d) + routine treatment (dietary control, glycaemic control, fosinopril) for 28 days</LI>
</UL>
<P>
<B>Control group</B>
</P>
<UL>
<LI>Routine treatment (dietary control, glycaemic control, fosinopril) for 28 days</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-02 17:39:27 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>SCr (&#956;mol/L)</LI>
<LI>UAER (&#956;g/min)</LI>
<LI>MAP (mm Hg)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2003-01-03 23:01:33 +1100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-17 12:25:27 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ma-2001">
<CHAR_METHODS MODIFIED="2010-02-08 17:22:50 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Design: Controlled, parallel, RCT</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-09 15:56:21 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Country: China</LI>
<LI>DKD (stage IV), as per <LINK REF="REF-Mogensen-1983" TYPE="REFERENCE">Mogensen 1983</LINK>; <LINK REF="REF-WHO-1999" TYPE="REFERENCE">WHO 1999</LINK>
</LI>
<LI>Duration of DM: 5-15 years</LI>
<LI>Age: 35-65 years</LI>
<LI>Number (treatment/control): 20/20</LI>
<LI>Gender (M/F): 24/16</LI>
</UL>
<P>
<B>Exclusion criteria</B>: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-07 14:45:38 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment group</B>
</P>
<UL>
<LI>PGE1 (150 &#956;g/d) + routine treatment (dietary control, insulin)</LI>
<LI>Treatment period: NS</LI>
</UL>
<P>
<B>Control group</B>
</P>
<UL>
<LI>Routine treatment (dietary control, insulin)</LI>
<LI>Treatment period: NS</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-17 12:25:27 +1100" MODIFIED_BY="[Empty name]"/>
<CHAR_NOTES MODIFIED="2003-01-03 23:27:26 +1100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-07 14:46:06 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2007">
<CHAR_METHODS MODIFIED="2010-02-09 15:12:08 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Design: Controlled, parallel, RCT</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-09 15:23:04 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Country: China</LI>
<LI>DKD, as per <LINK REF="REF-Mogensen-1983" TYPE="REFERENCE">Mogensen 1983</LINK>; <LINK REF="REF-WHO-1999" TYPE="REFERENCE">WHO 1999</LINK>
</LI>
<LI>Duration of DM: 10.4 ± 4.2 year</LI>
<LI>Number (treatment/control): 25/27</LI>
<LI>Age: 55.6 ± 12.8 year</LI>
<LI>Gender (M/F): 30/22</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Patients with infection, diabetic ketoacidosis or any other disease.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-07 14:46:06 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment group</B>
</P>
<UL>
<LI>PGE1 (20 &#956;g/d) + routine treatment (dietary control, insulin, nifedipine, metoprolol, losartan (100 mg/d)) for 28 days</LI>
</UL>
<P>
<B>Control group</B>
</P>
<UL>
<LI>Routine treatment (dietary control, insulin, nifedipine, metoprolol, losartan (100 mg/d)) for 28 days</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-02 17:39:33 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>SCr (&#956;mol/L)</LI>
<LI>Albuminuria (mg/24 h)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-28 01:23:40 +1000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-16 17:50:35 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tan-2004">
<CHAR_METHODS MODIFIED="2010-02-09 15:12:17 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Design: Controlled, parallel, RCT</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-16 17:50:35 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Country: China</LI>
<LI>DKD (stages III and IV), as per <LINK REF="REF-Mogensen-1983" TYPE="REFERENCE">Mogensen 1983</LINK>
</LI>
<LI>Duration of DM: 3-27 years</LI>
<LI>Number (treatment/control): 12/10</LI>
<LI>Age: 25-83 years</LI>
</UL>
<P>
<B>Exclusion criteria</B>: NS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-09 15:15:17 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment group</B>
</P>
<UL>
<LI>PGE1 (10 &#956;g/d) + routine treatment (dietary control, insulin) for 3 weeks</LI>
</UL>
<P>
<B>Control group</B>
</P>
<UL>
<LI>Routine treatment (dietary control, insulin) for 3 weeks</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-09 15:49:17 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Albuminuria (mg/24 h)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2003-01-03 23:42:54 +1100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-07 14:45:53 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yan-2002">
<CHAR_METHODS MODIFIED="2010-02-09 15:16:28 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Design: Controlled, parallel, RCT</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-09 15:24:02 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Country: China</LI>
<LI>DKD (stages III and IV), as per <LINK REF="REF-Mogensen-1983" TYPE="REFERENCE">Mogensen 1983</LINK>; <LINK REF="REF-WHO-1999" TYPE="REFERENCE">WHO 1999</LINK>
</LI>
<LI>Number (treatment/control): 41/30</LI>
<LI>Age: 68.27 ± 8.91 years</LI>
<LI>Gender (M/F): 43/28</LI>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Patients with infection; diabetic ketoacidosis and fever; coleitis; acute or chronic nephritis; urinary calculus; heart failure and other factors influencing the excretion of proteinuria.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-07 14:45:53 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment group</B>
</P>
<UL>
<LI>PGE1 (10 &#956;g/d) + routine treatment (dietary control, glycaemic control, exercise) for 4 weeks</LI>
</UL>
<P>
<B>Control group</B>
</P>
<UL>
<LI>Routine treatment (dietary control, glycaemic control, exercise) for 4 weeks</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-09 15:19:36 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>UAER (&#956;g/min)</LI>
<LI>Side effects of PGE1</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2003-01-03 23:51:27 +1100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-07 14:44:16 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2007">
<CHAR_METHODS MODIFIED="2010-02-09 15:20:27 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Design: Controlled, parallel, RCT</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-09 15:29:54 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Inclusion criteria</B>
</P>
<UL>
<LI>Country: China</LI>
<LI>DKD (IV stage), UAER as per (<LINK REF="REF-WHO-1999" TYPE="REFERENCE">WHO 1999</LINK>)</LI>
<LI>Duration of DKD</LI>
<UL>
<LI>Treatment group: 5.6 ± 3.4 years</LI>
<LI>Control group: 5.4 ± 3.1 years</LI>
</UL>
<LI>Number (treatment/control): 42/40 participants</LI>
<LI>Gender (M/F)</LI>
<UL>
<LI>Treatment group: 23/19</LI>
<LI>Control group: 22/18</LI>
</UL>
</UL>
<P>
<B>Exclusion criteria</B>
</P>
<UL>
<LI>Patients with UTI; heart failure; diabetic ketoacidosis and other kidney diseases.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-07 14:44:16 +1100" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment group</B>
</P>
<UL>
<LI>PGE1(10 &#956;g/d) + routine treatment (dietary control, glycaemic control, ACEi or ARB)</LI>
</UL>
<P>
<B>Control group</B>
</P>
<UL>
<LI>Xueshuantong (450 mg/d) + routine treatment (dietary control, glycaemic control, ACEi or ARB) for 14 days</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-02 17:39:38 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>SCr (&#956;mol/L)</LI>
<LI>Albuminuria (mg/24 h)</LI>
<LI>Change in BP (mm Hg)</LI>
<LI>Side effects of PGE1</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2003-01-03 23:38:30 +1100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACEi - angiotensin converting enzyme inhibitor; ARB - angiotensin receptor blockers; BP - blood pressure; DKD - diabetic kidney disease; DM - diabetes mellitus; MAP - mean arterial pressure; NS - not stated; PGE1 - prostaglandin E1; SCr - serum creatinine; UAER - urinary albumin excretion rate; UTI - urinary tract infection</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-03-17 12:25:33 +1100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-11-13 23:37:54 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cao-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-13 23:37:54 +1100" MODIFIED_BY="[Empty name]">
<P>We telephoned the author in 2008. The author summarized the past medical records. Telephone number: +86 024-25403783.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-18 02:00:56 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-18 02:00:56 +1000" MODIFIED_BY="[Empty name]">
<P>We telephoned the author in 2008. The author summarized the past medical records. Telephone number: +86 0755-26553111-91.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 17:43:20 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cui-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 17:43:20 +1100" MODIFIED_BY="[Empty name]">
<P>The treatment group received PGE1, dipyridamole and routine treatment (dietary control, glycaemia control and BP control), the control only received routine treatment (dietary control, glycaemia control and BP control), and we couldn't determine which drug (PGE1 or dipyridamole) was the active treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-18 02:04:03 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gan-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-18 02:04:03 +1000" MODIFIED_BY="[Empty name]">
<P>We telephoned the author in 2008. The author divided patients into groups at the author's discretion and had no protocol. Telephone number: +86 0818-6221243.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-17 16:54:22 +1100" MODIFIED_BY="han wang" STUDY_ID="STD-Gao-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-17 16:54:22 +1100" MODIFIED_BY="han wang">
<P>We telephoned the author in 2008. The author divided patients into groups according to the order the patients came to hospital, but sometimes patients were divided into groups at the author's discretion. Telephone number: +86 022-23086608.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 17:43:25 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ge-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 17:43:25 +1100" MODIFIED_BY="[Empty name]">
<P>The treatment group received PGE1, DNQKRT (a Chinese herbal mistura) and routine treatment (dietary control, glycaemia control and BP control), the control only received routine treatment (dietary control, glycaemia control and BP control), and we couldn't determine which drug (PGE1 or DNQKRT) was the active treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-09 15:39:49 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guo-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-09 15:39:49 +1100" MODIFIED_BY="[Empty name]">
<P>The treatment group received PGE1, Herba erigerontis (a Chinese herbal medicine) and routine treatment (dietary control, glycaemia control and fosinopril), the control only received routine treatment (dietary control, glycaemia control and fosinopril), and we couldn't determine which drug (PGE1 or Herba erigerontis) was the active treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-28 17:43:17 +1100" MODIFIED_BY="han wang" STUDY_ID="STD-Hu-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-28 17:43:17 +1100" MODIFIED_BY="han wang">
<P>We telephoned the author in 2008. Patients were divided into groups at the author's discretion. Telephone number: +86 021-56691101-6223</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-09 16:00:21 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-09 16:00:21 +1100" MODIFIED_BY="[Empty name]">
<P>Study included patients with DKD stage V which were analysed with stages III and IV.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-17 16:53:56 +1100" MODIFIED_BY="han wang" STUDY_ID="STD-Huang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-17 16:53:56 +1100" MODIFIED_BY="han wang">
<P>We telephoned the author in 2008. The author divided patients into groups according to the order the patients came to hospital, but sometimes patients were divided into groups at the author's discretion. Telephone number: +86 0631-5287627.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 17:51:54 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 17:51:54 +1100" MODIFIED_BY="[Empty name]">
<P>We telephoned the author in 2009, but the author refused more information. We couldn't determine whether if the study was an RCT. Telephone number: +86 0574-62619028.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-24 23:31:24 +1100" MODIFIED_BY="han wang" STUDY_ID="STD-Jiang-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-24 23:31:24 +1100" MODIFIED_BY="han wang">
<P>We telephoned the author in 2008. Patients were divided into groups at the author's discretion. Telephone number: +86 0768-2262612.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-09 15:39:50 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jiao-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-09 15:39:50 +1100" MODIFIED_BY="[Empty name]">
<P>The treatment group received PGE1, Salvia miltiorrhiza (a Chinese herbal medicine) and routine treatment (dietary control, glycaemia control and exercise), the control only received routine treatment (dietary control, glycaemia control and exercise), and we couldn't determine which drug (PGE1 or Salvia miltiorrhiza) was the active treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 17:43:30 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jiao-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 17:43:30 +1100" MODIFIED_BY="[Empty name]">
<P>The treatment group received PGE1, Huangqi (a Chinese herbal medicine) and routine treatment (dietary control, glycaemia control and BP control), the control only received routine treatment (dietary control, glycaemia control and BP control), and we couldn't determine which drug (PGE1 or Huangqi) was the active treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-13 23:39:21 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lai-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-13 23:39:21 +1100" MODIFIED_BY="[Empty name]">
<P>This is a before-after study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-28 17:49:53 +1100" MODIFIED_BY="han wang" STUDY_ID="STD-Li-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-28 17:49:53 +1100" MODIFIED_BY="han wang">
<P>This is not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-28 17:50:36 +1100" MODIFIED_BY="han wang" STUDY_ID="STD-Li-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-28 17:50:36 +1100" MODIFIED_BY="han wang">
<P>The author only compared the difference of two methods used for PGE1.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-18 02:06:31 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-18 02:06:31 +1000" MODIFIED_BY="[Empty name]">
<P>We telephoned the second author in 2009 because of absence of the first author. Patients were divided into groups at the author's discretion. Telephone number: +86 0591-87557768-7042.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 18:01:14 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liao-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 18:01:14 +1100" MODIFIED_BY="[Empty name]">
<P>We telephoned the author in 2008, but the author had no memory of the study. We couldn't determine whether it is an RCT. Telephone number: +86 0746-8486135.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-18 02:26:45 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-18 02:26:45 +1000" MODIFIED_BY="[Empty name]">
<P>We telephoned the author in 2009, the author summarized the past medical records. Telephone number: +86 0377-3219219.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 17:53:23 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2006b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 17:53:23 +1100" MODIFIED_BY="[Empty name]">
<P>We telephoned the author in 2008. Patients were divided into groups at the author's discretion. Telephone number: +86 0570-3056112.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 17:43:38 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2006c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 17:43:38 +1100" MODIFIED_BY="[Empty name]">
<P>The treatment group received PGE1, Huangqi (a Chinese herbal medicine) and routine treatment (dietary control, glycaemia control and BP control), the control only received routine treatment (dietary control, glycaemia control and BP control), and we couldn't determine which drug (PGE1 or Huangqi) was the active treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-13 23:40:00 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-13 23:40:00 +1100" MODIFIED_BY="[Empty name]">
<P>We telephoned the author in 2008. The author divided patients into groups according to the order the patients came to hospital, and treatment didn't at all accord with the protocol. Telephone number: +86 0534-2637224.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-17 13:49:38 +1100" MODIFIED_BY="han wang" STUDY_ID="STD-Liu-2007b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-17 13:49:38 +1100" MODIFIED_BY="han wang">
<P>We telephoned the author in 2008. The author divided patients into groups according to the order the patients came to hospital, and treatment didn't at all accord with the protocol. Telephone number: +86 0534-2637224.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 17:43:43 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meng-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 17:43:43 +1100" MODIFIED_BY="[Empty name]">
<P>The treatment group received PGE1, enalapril and routine treatment (dietary control, glycaemia control and BP control), the control only received routine treatment (dietary control, glycaemia control and BP control), and we couldn't determine which drug (PGE1 or enalapril) was the active treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-28 17:53:59 +1100" MODIFIED_BY="han wang" STUDY_ID="STD-Ninomiya-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-28 17:53:59 +1100" MODIFIED_BY="han wang">
<P>Treatment group and control group both received PGE1.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 17:53:52 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Niu-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 17:53:52 +1100" MODIFIED_BY="[Empty name]">
<P>We telephoned the author in 2008. The author didn't write the protocol, and in the proceeding of random patients were divided into groups at the author's discretion. Telephone number: +86 0757 83833633</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-13 23:40:10 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qin-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-13 23:40:10 +1100" MODIFIED_BY="[Empty name]">
<P>This is a before-after study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 17:43:49 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shou-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 17:43:49 +1100" MODIFIED_BY="[Empty name]">
<P>The treatment group received PGE1, Xueshuantong (a Chinese herbal medicine) and routine treatment (dietary control, glycaemia control and BP control), the control only received routine treatment (dietary control, glycaemia control and BP control), and we couldn't determine which drug (PGE1 or Xueshuantong) was the active treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-16 17:54:04 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-16 17:54:04 +1100" MODIFIED_BY="[Empty name]">
<P>We telephoned the author in 2009. Patients were divided into groups at the author's discretion and the author refused more information. Telephone number: +86 0431 84995222.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-28 17:56:46 +1100" MODIFIED_BY="han wang" STUDY_ID="STD-Tang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-28 17:56:46 +1100" MODIFIED_BY="han wang">
<P>We telephoned the author in 2008. The author divided patients into groups according to the order the patients came to hospital, and routine treatment didn't at all accord with the protocol. Telephone number: +86 0754 88550450-8154.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 17:44:01 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 17:44:01 +1100" MODIFIED_BY="[Empty name]">
<P>The treatment group received PGE1, Bailing capsule (a Chinese herbal mistura) and routine treatment (dietary control, glycaemia control and BP control), the control only received routine treatment (dietary control, glycaemia control and BP control), and we couldn't determine which drug (PGE1 or Bailing capsule) was the active treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 17:44:03 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 17:44:03 +1100" MODIFIED_BY="[Empty name]">
<P>The treatment group received PGE1, Yiqi-Yangyi-Huoxue (a Chinese herbal mistura) and routine treatment (dietary control, exercise, glycaemia control and BP control), the control only received routine treatment (dietary control, exercise, glycaemia control and BP control), and we couldn't determine which drug (PGE1 or Yiqi-Yangyi-Huoxue) was the active treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-18 02:14:43 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2004b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-18 02:14:43 +1000" MODIFIED_BY="[Empty name]">
<P>Came to the hospital, we were told patients were divided into groups at the author's discretion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-09 16:00:05 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-09 16:00:05 +1100" MODIFIED_BY="[Empty name]">
<P>Study included patients with DKD stage V which were analysed with stages III and IV.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-28 17:58:12 +1100" MODIFIED_BY="han wang" STUDY_ID="STD-Wang-2005b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-28 17:58:12 +1100" MODIFIED_BY="han wang">
<P>This is not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-18 01:26:52 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-18 01:26:52 +1000" MODIFIED_BY="[Empty name]">
<P>We telephoned the author in 2008. The author divided patients into groups according to the day the patients came to hospital, but in the proceeding of random patients were divided into groups at the author's discretion. Telephone number: +86 0311-86095318.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-28 17:58:53 +1100" MODIFIED_BY="han wang" STUDY_ID="STD-Wang-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-28 17:58:53 +1100" MODIFIED_BY="han wang">
<P>This is not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 17:44:08 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 17:44:08 +1100" MODIFIED_BY="[Empty name]">
<P>The treatment group received PGE1, irbesartan and routine treatment (dietary control, glycaemia control and BP control), the control only received routine treatment (dietary control, glycaemia control and BP control), and we couldn't determine which drug (PGE1 or irbesartan) was the active treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 17:44:10 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2007b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 17:44:10 +1100" MODIFIED_BY="[Empty name]">
<P>The treatment group received PGE1, low molecular heparin (LMH) and routine treatment (glycaemia control and BP control), the control only received routine treatment (glycaemia control and BP control), and we couldn't determine which drug (PGE1 or LMH) was the active treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 17:44:12 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 17:44:12 +1100" MODIFIED_BY="[Empty name]">
<P>The treatment group received PGE1, Huangqi (a Chinese herbal medicine) and routine treatment (glycaemia control and BP control), the control only received routine treatment (glycaemia control and BP control), and we couldn't determine which drug (PGE1 or Huangqi) was the active treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-17 16:55:08 +1100" MODIFIED_BY="han wang" STUDY_ID="STD-Xi-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-17 16:55:08 +1100" MODIFIED_BY="han wang">
<P>We telephoned the author in 2008. Patients were divided into groups at the author's discretion. Telephone number: +86 0513-83534086.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 17:44:20 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xie-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 17:44:20 +1100" MODIFIED_BY="[Empty name]">
<P>The treatment group received PGE1, Huangqi (a Chinese herbal medicine) and routine treatment (dietary control, glycaemia control and BP control), the control only received routine treatment (dietary control, glycaemia control and BP control), and we couldn't determine which drug (PGE1 or Huangqi) was the active treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-09 16:01:52 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xie-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-09 16:01:52 +1100" MODIFIED_BY="[Empty name]">
<P>Data error.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-09 16:02:01 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xiong-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-09 16:02:01 +1100" MODIFIED_BY="[Empty name]">
<P>Study included patients with DKD stage V which were analysed with stages III and IV.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-30 00:03:40 +1100" MODIFIED_BY="han wang" STUDY_ID="STD-Xu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-30 00:03:40 +1100" MODIFIED_BY="han wang">
<P>We telephoned the author in 2008. The author refused further information, we can't determinate whether it's an RCT. Telephone number: +86 020-62782330.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-13 23:41:55 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-13 23:41:55 +1100" MODIFIED_BY="[Empty name]">
<P>We telephoned the author in 2008. The author summarized the past medical records. Telephone number: +86 0523-4885277.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-17 16:55:13 +1100" MODIFIED_BY="han wang" STUDY_ID="STD-Yang-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-17 16:55:13 +1100" MODIFIED_BY="han wang">
<P>We telephoned the author in 2008. Patients were divided into groups at the author's discretion. Telephone number: +86 0513-6512215.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-09 16:02:13 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2007b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-09 16:02:13 +1100" MODIFIED_BY="[Empty name]">
<P>Study included patients with DKD stage V which were analysed with stages III and IV.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-18 02:21:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-18 02:21:21 +1000" MODIFIED_BY="[Empty name]">
<P>We telephoned the author in 2008, but the author refused further information. We couldn't determine whether it is an RCT. Telephone number: +86 0536-8192511.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 17:44:21 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 17:44:21 +1100" MODIFIED_BY="[Empty name]">
<P>The treatment group received PGE1, Huangqi (a Chinese herbal medicine) and routine treatment (dietary control, glycaemia control and BP control), the control only received routine treatment (dietary control, glycaemia control and BP control), and we couldn't determine which drug (PGE1 or Huangqi) was the active treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-18 01:35:30 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-18 01:35:30 +1000" MODIFIED_BY="[Empty name]">
<P>We telephoned the author in 2009. The author summarized the past medical records. Telephone number: +86 0711-3232002.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-18 02:16:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-18 02:16:48 +1000" MODIFIED_BY="[Empty name]">
<P>We telephoned the author in 2008. The author summarized the past medical records. Telephone number: +86 0537-8708826.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 18:01:15 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 18:01:15 +1100" MODIFIED_BY="[Empty name]">
<P>We telephoned the author in 2009. The author refused any information about the study. Telephone number: +86 0668-5342622.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-09 16:02:26 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2006b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-09 16:02:26 +1100" MODIFIED_BY="[Empty name]">
<P>Error in randomisation method. All patients were divided into two groups by means of random sampling.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-28 18:11:35 +1100" MODIFIED_BY="han wang" STUDY_ID="STD-Zhao-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-28 18:11:35 +1100" MODIFIED_BY="han wang">
<P>We telephoned the author in 2008, when we identified the randomisation procedure and other methodological issues, the author denied the fact he wrote the paper, refused further information. We couldn't determine whether it is an RCT. Telephone number: +86 0739-5295434.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 17:44:22 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2007b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 17:44:22 +1100" MODIFIED_BY="[Empty name]">
<P>The treatment group received PGE1, TSQ (a Chinese herbal mistura) and routine treatment (dietary control, glycaemia control and BP control), the control only received routine treatment (dietary control, glycaemia control and BP control), and we couldn't determine which drug (PGE1 or TSQ) was the active treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-25 16:03:07 +1100" MODIFIED_BY="han wang" STUDY_ID="STD-Zheng-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-25 16:03:07 +1100" MODIFIED_BY="han wang">
<P>We telephoned the author in 2008, but the author refused further information. We couldn't determine whether it is an RCT. Telephone number: +86 0593-2876989.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-18 01:34:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhong-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-18 01:34:53 +1000" MODIFIED_BY="[Empty name]">
<P>We telephoned the author in 2009, but the author refused further information. We couldn't determine whether it is an RCT. Telephone number: +86 0539 8381020-7130.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-25 16:03:16 +1100" MODIFIED_BY="han wang" STUDY_ID="STD-Zhou-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-25 16:03:16 +1100" MODIFIED_BY="han wang">
<P>We telephoned the author in 2008. The author summarized the past medical records. Telephone number: +86 0516-8369022.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-09 16:03:02 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-09 16:03:02 +1100" MODIFIED_BY="[Empty name]">
<P>Patients with exercise-induced albuminuria were enrolled.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-04-18 01:57:17 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-11-11 05:06:12 +1100" MODIFIED_BY="han wang" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-02-09 15:30:49 +1100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-02-09 15:30:42 +1100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:15:45 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:15:59 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ma-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:16:11 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:15:32 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tan-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:19:40 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yan-2002">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:30:42 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-02-09 15:30:44 +1100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:15:49 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:16:01 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ma-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:16:14 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:15:35 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tan-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:19:42 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yan-2002">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:30:44 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-02-09 15:30:47 +1100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.04" NO="4">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-02-09 15:15:51 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-02-09 15:16:04 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ma-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-02-09 15:16:17 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-02-09 15:15:37 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tan-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-02-09 15:19:44 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yan-2002">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2010-02-09 15:30:47 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2003-01-03 23:37:18 +1100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>proteinuria</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>serum creatinine</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2003-01-03 23:37:18 +1100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2003-01-03 23:37:18 +1100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2010-02-09 15:30:49 +1100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Intention-to-treat analysis</NAME>
<DESCRIPTION>
<P>Was intention-to-treat analysis undertaken</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:15:54 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:16:06 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ma-2001">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:16:20 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:15:39 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tan-2004">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:19:46 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yan-2002">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:30:49 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>NS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-03-17 12:22:26 +1100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-03-07 14:10:39 +1100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>PGE1 + routine treatment versus routine treatment</NAME>
<CONT_OUTCOME CHI2="4.747504897396029" CI_END="-21.279419979711932" CI_START="-75.28676128963386" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-48.283090634672895" ESTIMABLE="YES" I2="36.80891194771641" I2_Q="73.55001505795867" ID="CMP-001.01" MODIFIED="2010-03-07 13:19:30 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1912477340076929" P_Q="0.05184637195074182" P_Z="4.5754479251651356E-4" Q="3.7807204888443424" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="265.1737811173568" TOTALS="YES" TOTAL_1="83" TOTAL_2="74" UNITS="" WEIGHT="100.0" Z="3.504453891302981">
<NAME>Urinary albumin excretion rate (µg/min)</NAME>
<GROUP_LABEL_1>PGE1</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PGE1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.3102545944983505" CI_END="-24.412129563865157" CI_START="-53.829128891262364" DF="1" EFFECT_SIZE="-39.12062922756376" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" MODIFIED="2010-02-08 17:17:52 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5775241058164369" P_Z="1.858370865029513E-7" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="35" WEIGHT="91.63021270100826" Z="5.212973864887674">
<NAME>Incipient DKD</NAME>
<CONT_DATA CI_END="-20.506940363966077" CI_START="-53.49305963603392" EFFECT_SIZE="-37.0" ESTIMABLE="YES" MEAN_1="99.0" MEAN_2="136.0" MODIFIED="2009-04-20 02:06:04 +1000" MODIFIED_BY="[Empty name]" ORDER="7" SD_1="21.0" SD_2="32.0" SE="8.414980972165342" STUDY_ID="STD-Lin-2004" TOTAL_1="20" TOTAL_2="21" WEIGHT="56.497424141639975"/>
<CONT_DATA CI_END="-14.850081465046031" CI_START="-79.86991853495397" EFFECT_SIZE="-47.36" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="92.36" MODIFIED="2009-04-20 02:07:39 +1000" MODIFIED_BY="[Empty name]" ORDER="8" SD_1="35.31" SD_2="54.96" SE="16.586997920057744" STUDY_ID="STD-Yan-2002" TOTAL_1="21" TOTAL_2="14" WEIGHT="35.13278855936829"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6565298140533359" CI_END="-39.633258774316715" CI_START="-215.62869519584092" DF="1" EFFECT_SIZE="-127.63097698507882" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" MODIFIED="2010-02-08 17:18:06 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4177880176660551" P_Z="0.0044731552655325035" STUDIES="2" TAU2="0.0" TOTAL_1="42" TOTAL_2="39" WEIGHT="8.369787298991739" Z="2.8427114167128655">
<NAME>Clinical DKD</NAME>
<CONT_DATA CI_END="210.31780462796758" CI_START="-932.3178046279676" EFFECT_SIZE="-361.0" ESTIMABLE="YES" MEAN_1="1682.0" MEAN_2="2043.0" MODIFIED="2009-04-20 02:11:48 +1000" MODIFIED_BY="[Empty name]" ORDER="5" SD_1="840.0" SD_2="1103.0" SE="291.49403210183937" STUDY_ID="STD-Lin-2004" TOTAL_1="22" TOTAL_2="23" WEIGHT="0.22270852187874857"/>
<CONT_DATA CI_END="-32.89950655555323" CI_START="-211.02049344444674" EFFECT_SIZE="-121.95999999999998" ESTIMABLE="YES" MEAN_1="261.85" MEAN_2="383.81" MODIFIED="2009-04-20 02:10:35 +1000" MODIFIED_BY="[Empty name]" ORDER="6" SD_1="98.46" SD_2="159.0" SE="45.439862235706656" STUDY_ID="STD-Yan-2002" TOTAL_1="20" TOTAL_2="16" WEIGHT="8.14707877711299"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="17.918086210725818" CI_END="-65.8352220283007" CI_START="-221.47523741730836" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-143.65522972280453" ESTIMABLE="YES" I2="94.41904683212543" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2010-03-07 14:10:10 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.306218064107579E-5" P_Q="1.0" P_Z="2.967957351040897E-4" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="2983.7599037037025" TOTALS="YES" TOTAL_1="37" TOTAL_2="37" UNITS="" WEIGHT="100.0" Z="3.6180808096657437">
<NAME>Albuminuria (mg/24 h)</NAME>
<GROUP_LABEL_1>PGE1</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PGE1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-95.85796619068712" CI_START="-115.7420338093129" EFFECT_SIZE="-105.80000000000001" ESTIMABLE="YES" MEAN_1="89.6" MEAN_2="195.4" MODIFIED="2009-04-20 02:42:22 +1000" MODIFIED_BY="[Empty name]" ORDER="19" SD_1="15.2" SD_2="21.1" SE="5.072559438711316" STUDY_ID="STD-Sun-2007" TOTAL_1="25" TOTAL_2="27" WEIGHT="52.383358839239534"/>
<CONT_DATA CI_END="-149.85773041417306" CI_START="-220.7422695858269" EFFECT_SIZE="-185.29999999999998" ESTIMABLE="YES" MEAN_1="223.1" MEAN_2="408.4" MODIFIED="2009-04-20 02:42:22 +1000" MODIFIED_BY="[Empty name]" ORDER="20" SD_1="45.4" SD_2="39.4" SE="18.083122886640275" STUDY_ID="STD-Tan-2004" TOTAL_1="12" TOTAL_2="10" WEIGHT="47.61664116076046"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2010-03-07 14:10:22 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="20" TOTAL_2="20" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria (g/24 h)</NAME>
<GROUP_LABEL_1>PGE1</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PGE1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-81.65966024388871" CI_START="-518.3403397561112" EFFECT_SIZE="-300.0" ESTIMABLE="YES" MEAN_1="880.0" MEAN_2="1180.0" MODIFIED="2009-04-20 02:18:41 +1000" MODIFIED_BY="[Empty name]" ORDER="10" SD_1="310.0" SD_2="390.0" SE="111.40017953306898" STUDY_ID="STD-Ma-2001" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="23.2491629329154" CI_END="0.4431192321150448" CI_START="-15.614101477390594" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.585491122637775" ESTIMABLE="YES" I2="87.09630962346306" I2_Q="86.43009846561748" ID="CMP-001.04" MODIFIED="2010-03-07 13:17:46 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="3.583066344159391E-5" P_Q="6.303459707612813E-4" P_Z="0.06405618034441343" Q="14.73850045950982" RANDOM="YES" SCALE="50.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="57.41904254424846" TOTALS="YES" TOTAL_1="87" TOTAL_2="91" UNITS="" WEIGHT="100.0" Z="1.8517886344574095">
<NAME>Serum creatinine (µmol/L)</NAME>
<GROUP_LABEL_1>PGE1</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PGE1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.561957485499663" CI_START="-6.561957485499663" DF="0" EFFECT_SIZE="-1.5" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" MODIFIED="2010-03-07 13:08:03 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5613804419725492" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="27" WEIGHT="26.181784192337528" Z="0.5807923091475512">
<NAME>Incipient and clinical DKD</NAME>
<CONT_DATA CI_END="3.561957485499663" CI_START="-6.561957485499663" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="70.62" MEAN_2="72.12" MODIFIED="2009-04-20 02:27:23 +1000" MODIFIED_BY="[Empty name]" ORDER="14" SD_1="8.76" SD_2="9.86" SE="2.582678827482412" STUDY_ID="STD-Sun-2007" TOTAL_1="25" TOTAL_2="27" WEIGHT="26.181784192337528"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.646271883306695" CI_START="-12.353728116693304" DF="0" EFFECT_SIZE="-7.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" MODIFIED="2010-03-07 13:13:21 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.010387578192163897" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="25.862542843834177" Z="2.562653088228599">
<NAME>Incipient DKD</NAME>
<CONT_DATA CI_END="-1.646271883306695" CI_START="-12.353728116693304" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="62.0" MEAN_2="69.0" MODIFIED="2009-04-20 02:25:56 +1000" MODIFIED_BY="[Empty name]" ORDER="11" SD_1="7.6" SD_2="9.8" SE="2.731544129852808" STUDY_ID="STD-Lin-2004" TOTAL_1="20" TOTAL_2="21" WEIGHT="25.862542843834177"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.51066247340558" CI_END="3.71834145418398" CI_START="-25.627113127438264" DF="1" EFFECT_SIZE="-10.954385836627141" ESTIMABLE="YES" I2="88.25003337725077" ID="CMP-001.04.03" MODIFIED="2010-03-07 13:13:21 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0035307274579310377" P_Z="0.14339276665769723" STUDIES="2" TAU2="99.2812875494071" TOTAL_1="42" TOTAL_2="43" WEIGHT="47.9556729638283" Z="1.4632727295347951">
<NAME>Clinical DKD</NAME>
<CONT_DATA CI_END="-13.040506846470887" CI_START="-22.959493153529113" EFFECT_SIZE="-18.0" ESTIMABLE="YES" MEAN_1="86.0" MEAN_2="104.0" MODIFIED="2009-04-20 02:24:44 +1000" MODIFIED_BY="[Empty name]" ORDER="12" SD_1="7.0" SD_2="9.8" SE="2.530400146456242" STUDY_ID="STD-Lin-2004" TOTAL_1="22" TOTAL_2="23" WEIGHT="26.29144114512981"/>
<CONT_DATA CI_END="5.77278215523425" CI_START="-11.77278215523425" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="93.8" MEAN_2="96.8" MODIFIED="2009-04-20 02:23:24 +1000" MODIFIED_BY="[Empty name]" ORDER="13" SD_1="14.5" SD_2="13.8" SE="4.475991510268982" STUDY_ID="STD-Ma-2001" TOTAL_1="20" TOTAL_2="20" WEIGHT="21.66423181869849"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0245610861840575E-28" CI_END="0.17448824259106321" CI_START="-2.5744882425910554" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1999999999999962" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2010-03-07 14:10:39 +1100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9999999999999919" P_Q="0.9999999999999919" P_Z="0.08705326154286926" Q="1.0245610861840575E-28" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="44" UNITS="" WEIGHT="100.00000000000001" Z="1.7111508913414668">
<NAME>Mean arterial pressure (mm Hg)</NAME>
<GROUP_LABEL_1>PGE1</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PGE1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7911913066008136" CI_START="-3.191191306600791" DF="0" EFFECT_SIZE="-1.1999999999999886" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" MODIFIED="2009-04-20 02:31:42 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.23753095956732329" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="21" WEIGHT="47.649251560181426" Z="1.1811807201303572">
<NAME>IDN</NAME>
<CONT_DATA CI_END="0.7911913066008136" CI_START="-3.191191306600791" EFFECT_SIZE="-1.1999999999999886" ESTIMABLE="YES" MEAN_1="102.4" MEAN_2="103.6" MODIFIED="2009-04-20 02:31:42 +1000" MODIFIED_BY="[Empty name]" ORDER="17" SD_1="3.3" SD_2="3.2" SE="1.0159325999391138" STUDY_ID="STD-Lin-2004" TOTAL_1="20" TOTAL_2="21" WEIGHT="47.649251560181426"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6996762000024181" CI_START="-3.099676200002424" DF="0" EFFECT_SIZE="-1.2000000000000028" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" MODIFIED="2009-04-20 02:32:37 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.21568531565171412" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="23" WEIGHT="52.35074843981859" Z="1.2380829856399072">
<NAME>CDN</NAME>
<CONT_DATA CI_END="0.6996762000024181" CI_START="-3.099676200002424" EFFECT_SIZE="-1.2000000000000028" ESTIMABLE="YES" MEAN_1="102.6" MEAN_2="103.8" MODIFIED="2009-04-20 02:32:37 +1000" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="3.1" SD_2="3.4" SE="0.9692403610407254" STUDY_ID="STD-Lin-2004" TOTAL_1="22" TOTAL_2="23" WEIGHT="52.35074843981859"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-03-07 13:21:07 +1100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>PGE1 + routine treatment versus other drugs + routine treatment</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2010-03-07 13:20:18 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="42" TOTAL_2="40" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Albuminuria (mg/24 h)</NAME>
<GROUP_LABEL_1>PGE1</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PGE1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other drugs</GRAPH_LABEL_2>
<CONT_DATA CI_END="-452.92555259165385" CI_START="-867.0744474083461" EFFECT_SIZE="-660.0" ESTIMABLE="YES" MEAN_1="1120.0" MEAN_2="1780.0" MODIFIED="2003-01-04 00:22:53 +1100" MODIFIED_BY="[Empty name]" ORDER="1" SD_1="430.0" SD_2="520.0" SE="105.65216965297472" STUDY_ID="STD-Zhang-2007" TOTAL_1="42" TOTAL_2="40" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2010-03-07 13:20:35 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="42" TOTAL_2="40" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Serum creatinine (µmol/L)</NAME>
<GROUP_LABEL_1>PGE1</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PGE1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other drugs</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.283695294652051" CI_START="-2.283695294652051" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="84.0" MEAN_2="83.0" MODIFIED="2003-01-04 00:24:46 +1100" MODIFIED_BY="[Empty name]" ORDER="2" SD_1="7.0" SD_2="8.1" SE="1.675385527771643" STUDY_ID="STD-Zhang-2007" TOTAL_1="42" TOTAL_2="40" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2010-03-07 13:20:52 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="42" TOTAL_2="40" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Systolic BP (mm Hg)</NAME>
<GROUP_LABEL_1>PGE1</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PGE1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other drugs</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.520133762611648" CI_START="-9.520133762611648" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="129.0" MEAN_2="132.0" MODIFIED="2003-01-04 00:25:45 +1100" MODIFIED_BY="[Empty name]" ORDER="3" SD_1="14.0" SD_2="16.0" SE="3.32665998663324" STUDY_ID="STD-Zhang-2007" TOTAL_1="42" TOTAL_2="40" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2010-03-07 13:21:07 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="42" TOTAL_2="40" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Diastolic BP (mm Hg)</NAME>
<GROUP_LABEL_1>PGE1</GROUP_LABEL_1>
<GROUP_LABEL_2>Other drugs</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PGE1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other drugs</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.24952897996711432" CI_START="-6.249528979967114" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="83.0" MEAN_2="86.0" MODIFIED="2003-01-04 00:26:32 +1100" MODIFIED_BY="[Empty name]" ORDER="4" SD_1="8.0" SD_2="7.0" SE="1.6579534142458658" STUDY_ID="STD-Zhang-2007" TOTAL_1="42" TOTAL_2="40" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-03-17 12:22:19 +1100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="079 flow chart.PNG" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-01-11 15:30:52 +1100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow chart showing study selection process</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArkAAAJ8CAIAAAB1GS7kAAA3tUlEQVR42u3dO3bjuhKo4TPBnocH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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-03-02 16:44:10 +1100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-03-02 16:37:27 +1100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-06-11 11:21:47 +1000" MODIFIED_BY="Gail Y Higgins">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2010-02-08 17:16:13 +1100" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD>
<OL>
<LI>Alprostadil/</LI>
<LI>(alprostadil$ or aloprostadil or alprox).tw.</LI>
<LI>prostaglandin E1$.tw.</LI>
<LI>(pge1 or "pg E1" or "pge 1").tw.</LI>
<LI>caverject.tw.</LI>
<LI>muse.tw.</LI>
<LI>(prostavasin$ or prostivas).tw.</LI>
<LI>"prostin$ vr".tw.</LI>
<LI>viridal.tw.</LI>
<LI>topiglan.tw.</LI>
<LI>femprox.tw.</LI>
<LI>befar.tw.</LI>
<LI>or/1-12</LI>
<LI>Diabetic Nephropathies/</LI>
<LI>diabetic nephropath$.tw.</LI>
<LI>((diabetic or diabetes) and (kidney disease$ or renal disease$ or nephro$ or nephrit$ or glomerulo$)).tw.</LI>
<LI>Diabetes Mellitus/ or exp diabetes mellitus, type 1/ or exp diabetes mellitus, type 2/</LI>
<LI>(IDDM or NIDDM).tw.</LI>
<LI>or/14-18</LI>
<LI>and/13,19</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL</P>
</TD>
<TD>
<OL>
<LI>MeSH descriptor Alprostadil, this term only</LI>
<LI>(alprostadil* or aloprostadil or alprox) in Clinical Trials</LI>
<LI>(prostaglandin E1*) in Clinical Trials</LI>
<LI>(pge1 or "pg E1" or "pge 1") in Clinical Trials</LI>
<LI>(caverject) in Clinical Trials</LI>
<LI>(muse) in Clinical Trials</LI>
<LI>(prostavasin* or prostivas) in Clinical Trials</LI>
<LI>"prostin* vr" in Clinical Trials</LI>
<LI>(viridal) in Clinical Trials</LI>
<LI>(topiglan) in Clinical Trials</LI>
<LI>(femprox) in Clinical Trials</LI>
<LI>(befar) in Clinical Trials</LI>
<LI>(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)</LI>
<LI>(diabetic nephropath*) in Clinical Trials</LI>
<LI>((diabetic or diabetes) and (kidney disease* or renal disease* or nephro* or nephrit* or glomerulo*)) in Clinical Trials</LI>
<LI>MeSH descriptor Diabetes Mellitus, this term only</LI>
<LI>MeSH descriptor Diabetes Mellitus, Type 1 explode all trees</LI>
<LI>MeSH descriptor Diabetes Mellitus, Type 2 explode all trees</LI>
<LI>(IDDM or NIDDM) in Clinical Trials</LI>
<LI>(#14 OR #15 OR #16 OR #17 OR #18 OR #19)</LI>
<LI>(#13 AND #20)</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD>
<OL>
<LI>Prostaglandin E1/</LI>
<LI>prostaglandin E1$.tw.</LI>
<LI>(alprostadil$ or aloprostadil or alprox).tw.</LI>
<LI>(pge1 or "pg E1" or "pge 1").tw.</LI>
<LI>caverject.tw.</LI>
<LI>muse.tw.</LI>
<LI>(prostavasin$ or prostivas).tw.</LI>
<LI>"prostin$ vr".tw.</LI>
<LI>viridal.tw.</LI>
<LI>topiglan.tw.</LI>
<LI>femprox.tw.</LI>
<LI>befar.tw.</LI>
<LI>alista.tw.</LI>
<LI>or/1-13</LI>
<LI>Diabetic Nephropathy/</LI>
<LI>diabetic nephropath$.tw.</LI>
<LI>((diabetic or diabetes) and (kidney disease$ or renal disease$ or nephro$ or nephrit$ or glomerulo$)).tw.</LI>
<LI>diabetes mellitus/ or insulin dependent diabetes mellitus/ or non insulin dependent diabetes mellitus/</LI>
<LI>(IDDM or NIDDM).tw.</LI>
<LI>or/15-19</LI>
<LI>and/14,20</LI>
</OL>
<P/>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-03-02 16:44:10 +1100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-03-02 16:44:04 +1100" MODIFIED_BY="[Empty name]">Quality assessment checklist</TITLE>
<APPENDIX_BODY MODIFIED="2010-03-02 16:44:10 +1100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<UL>
<LI>Adequate (A): Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study.</LI>
<LI>Unclear (B): Randomisation stated but no information on method used is available.</LI>
<LI>Inadequate (C): Method of randomisation used such as alternate medical record numbers or unsealed envelopes; any information in the study that indicated that investigators or participants could influence intervention group.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding</HEADING>
<UL>
<LI>Blinding of investigators: Yes/no/not stated.</LI>
<LI>Blinding of participants: Yes/no/not stated.</LI>
<LI>Blinding of outcome assessor: Yes/no/not stated.</LI>
<LI>Blinding of data analysis: Yes/no/not stated.</LI>
</UL>
<P>The above are considered not blinded if the treatment group can be identified in &gt; 20% of participants because of the side effects of treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intention-to-treat</HEADING>
<UL>
<LI>Yes: Specifically reported by authors that intention-to-treat analysis was undertaken and this was confirmed on study assessment.</LI>
<LI>Yes: Not stated but confirmed on study assessment.</LI>
<LI>No: Not reported and lack of intention-to-treat analysis confirmed on study assessment (patients who were randomised were not included in the analysis because they did not receive the study intervention, they withdrew from the study or they were not included because of protocol violation).</LI>
<LI>No: Stated but not confirmed upon study assessment.</LI>
<LI>Not stated.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Completeness to follow-up</HEADING>
<P>Per cent of participants excluded or lost to follow-up.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>